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ABSTRACT 
 
HIV-1 has the ability to rapidly diversify and adapt to changes in its 
environment, such as evading the host immune response, altering cell tropism, 
and developing resistance to antiretroviral drugs. Minority HIV-1 variants have 
been shown to be of clinical significance, especially those with non-nucleoside 
reverse transcriptase inhibitor (NNRTI) drug resistance mutations or 
determinants of CXCR4 phenotype (X4-virus). In this thesis a next generation 
sequencing technology, ultra-deep pyrosequencing (UDPS), has been used to 
dissect HIV-1 quasispecies in infected patients to study the evolution of drug 
resistance and cell tropism. The depth of UDPS depends on the number of viral 
templates that can be successfully extracted and amplified from a plasma sample, 
the error rate of PCR and UDPS, and the efficiency of cleaning the UDPS data from 
such errors. For this reason, we developed an experimental design that allows 
high recovery of HIV-1 templates and an efficient data cleaning strategy. Our data 
cleaning strategy reduced the UDPS error rate approximately 10-fold. We 
carefully evaluated the performance of our UDPS protocol and found that the 
repeatability of detection of major as well as minor variants in patient plasma 
samples was good. This indicated that the experimental noise introduced during 
RNA extraction, cDNA synthesis, PCR and UDPS was low. However, for rare 
variants in vitro PCR recombination and effects of sequence direction need to be 
considered. Finally, the design of primers for PCR amplification is of special 
importance during UDPS, since we observed that primer-related selective 
amplification can skew the frequency estimates of genetic variants.  
 
We investigated the levels of pre-existing drug resistance mutations in plasma 
samples from five treatment-naive patients. In four of five patients we found low 
levels of pre-existing drug resistance mutations at two positions (M184I, 
T215A/I), whereas other mutations (M184V, Y181C, Y188C and T215Y/F) were 
not detected. During treatment failure and treatment interruption, we found 
almost complete replacement of wild-type and drug-resistant variants, 
respectively. This implies that the proportion of minority variants with drug 
resistance in patients with previous treatment failure or transmitted drug 
resistance can be too low to be detectible even with highly sensitive UDPS. In 
another study, the HIV-1 populations from three patients with HIV-1 populations 
that switched coreceptor use were investigated longitudinally. UDPS analysis 
showed that the X4-virus that emerged after coreceptor switch was not detected 
during primary HIV-1 infection (PHI) and that the X4 population most probably 
evolved from the CCR5-using population during the course of infection rather than 
was transmitted as minor variants. Moreover, one to three major variants were 
found during PHI, supporting that infection usually is established with one or just 
a few viral particles.  
 
The frequency and type of errors that occurred during UDPS were investigated. 
The errors that remained after data cleaning were significantly more often 
transitions than transversions, which indicates that a substantial proportion of 
errors were introduced during PCR rather than UDPS itself. This affects the limits 
of detection of minority mutations since UDPS analyses of HIV-1 are preceded by a 
PCR step. To further reduce the UDPS error rate we developed a new, improved  
  
 
 
 
 
methodology, based on re-sequencing of molecularly tagged template molecules. 
Preliminary results showed that this method has the potential to increase the 
sensitivity of UDPS analyses 1000-fold and thus is close to error-free.  
 
Taken together, this thesis adds knowledge on the use of UDPS to gain new 
insights in HIV evolution and resistance and is relevant for the possible future 
clinical use of this technology.  
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1 AIMS 
 
The specific aims of my thesis were: 
 
 
Paper I  To investigate, by ultra-deep pyrosequencing (UDPS), the presence 
of drug resistance mutations in treatment naïve HIV-1 infected 
patients and the dynamics of drug resistance development and 
reversion during treatment initiation and discontinuation.  
 
Paper II To evaluate the quality and reproducibility of the UDPS technology 
in analysis of HIV-1 pol gene variation. 
 
Paper III To investigate if CXCR4-using virus is present as a minority species 
already during primary HIV-1 infection in patients whose virus 
later switches to CXCR4 use.  
 
Paper IV To investigate the characteristics and source of errors introduced 
by UDPS and to develop methods to reduce the error frequency. 
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2 THE HUMAN IMMUNODEFICIENCY VIRUS 
 
 
2.1 THE BEGINNING OF THE HIV PANDEMIC 
The origin of the human immunodeficiency virus (HIV) virus has been traced to 
the simian immunodeficiency viruses (SIV), found in African apes and monkeys 
[1-3]. HIV-1 was introduced to humans through several cross-species 
transmissions that are estimated to have occurred during the first part of 
twentieth century in West Central Africa [3-5] but it was only about 30 years ago 
the recognition and identification of the virus began. In 1981 opportunistic 
diseases, such as Pneumocystis carinii pneumonia and Kaposi’s sarcoma, along 
with immune suppression was reported in young, previously healthy 
homosexual men in New York City and California [6, 7]. Additional opportunistic 
complications were soon described, including mycobacterial infections, 
toxoplasmosis, invasive fungal infections, and non-Hodgkin's lymphoma. The 
disease was given the name acquired immunodeficiency syndrome (AIDS) [8] 
but the cause of the disease remained unknown for two more years. The first 
clear evidence that AIDS was caused by an infectious agent came when a child 
who received a blood transfusion died of AIDS related opportunistic infections 
[9]. In 1983, the French researchers Dr Luc Montagnier and Dr Francoise Barre-
Sinoussi isolated HIV [10] and in 2008 they received the Nobel Prize for their 
finding. Since the discovery of HIV, extensive research has shed light on one of 
the fastest evolving organisms on earth [11]. The ability to rapidly diversify 
allows HIV to evade the host’s immune system [12], alter its cell tropism, and 
develop resistance to antiretroviral drugs [13]. 
2.1.1  Origin of HIV 
SIVs are known to naturally infect approximately 40 different species of Old World 
monkeys and apes in sub-Saharan Africa [14]. The zoonotic transmission events of 
some of these SIVs have resulted in different forms of HIV (type or group) (Figure 
1). The transmissions from West Central African chimpanzees (Pan troglodytes 
troglodytes) and from sooty mangabeys (Cercocebus atys atys) have been 
established as HIV type 1 (HIV-1) and HIV type 2 (HIV-2), respectively [1].  The 
time to the most common recent ancestor (tMRCA) and the origin for HIV-1 and 
HIV-2 have been estimated using phylogenetic analyses and sequence data with 
known sampling dates. The result from these studies suggest that the tMRCA for 
HIV-1 and HIV-2 dates back to 1910 [4] and 1940 [15], respectively. 
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Figure 1. Evolutionary history of the primate lentiviruses. Maximum likelihood tree of the viral pol 
gene. (Kindly provided by Helena Skar). 
 
Interestingly, it has been shown that SIV has been present in African primates for 
more than 32 000 years [16]. Thus, transmission of SIV to humans has been 
possible also in the past, however why only the transmissions occurring about 
100 years ago where successful remains unknown. This may be explained by  
social and behavioral changes such as migrations, urbanization [4, 5] and 
colonization, together with war and health programs [17]. 
  
2.1.2 Global spread 
Since 1981, more than 60 million people have been infected with HIV-1, and more 
than 20 million have died from AIDS related disease. The HIV-1 virus has spread 
to all continents but the most affected part of the world is sub-Saharan Africa, 
where 22.9 million people live with HIV today [18] (Figure 2). In the western 
world, HIV-1 infections are more common among populations at higher risk, such 
as men who have sex with men (MSM), intravenous drug users and immigrants 
[19]. According to UNAIDS, the global spread of HIV appears to have peaked in 
1997, however still the number of people living with HIV is increasing. It could be 
the refection of combined effects of continued high rates of HIV transmission and 
the beneficial impact of antiretroviral treatment [20]. 
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Figure 2. The global HIV-1 subtype distribution. Reprinted with permission from [21].  
 
 
2.2  HIV VIROLOGY 
2.2.1 Structure and genome  
HIV belongs to the Lentivirus genus of the Retroviridae family. Retroviruses are 
enveloped viruses that contain two copies of positive-sense single-stranded RNA 
molecules, which are non-covalently linked at the 5’-end. The HIV virus contains a 
conical nucleocapsid that surrounds the viral nucleic acid as well as the viral 
enzymes, reverse transcriptase (RT), protease (PR) and integrase (IN), which are 
required for the early replication events. The envelope consists mainly of host cell 
lipid bilayer membrane together with viral trimeric glycoprotein gp41 covalently 
linked to the external trimeric gp120 (Figure 3). 
 
 
 
Figure 3. Schematic structure of the HIV particle. Reprinted with permission from [22]. 
  
The HIV genome is approximately 10,000 nucleotides in length. Like other 
retroviruses, it has three major structural genes: group-specific antigens (gag), 
polymerase (pol) and envelope (env) (Figure 4). The HIV-1 gag gene encodes the 
polyprotein precursor p55, which is processed into p24 (capsid), p17 (matrix), p7 
(nucleocapsid), and p6 by the viral protease. HIV-1 pol encodes the viral enzymes 
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PR, RT and IN. The gag and pol genes are produced as Gag or Gag-Pol precursor 
polyproteins that are cleaved by the viral PR into the functional proteins. The env 
gene encodes the viral polyprotein gp160/gp140 that is cleaved into the external 
glycoprotein gp120 and the transmembrane protein gp41, which are important 
for viral attachment to the host CD4 receptor and fusion with the host membrane. 
In addition, HIV-1 has two regulatory genes: tat, rev and four accessory genes: vif, 
vpr, vpu and nef. These genes are important for the viral lifecycle of HIV-1, 
summarized in Table 1.  
 
 
 
 
Figure 4. The genomic organization of HIV-1.  
 
Table 1. Regulatory and accessory proteins 
Gene/ 
Protein 
 
Time of 
expression 
Present 
in virion 
Function 
tat/Tat Early No Transactivator of HIV gene expression. It 
binds to the TAR RNA element to facilitate 
initiation and elongation of viral 
transcription. 
 
rev/Rev Early No Regulation of viral expression. Permits un-
spliced mRNA to exit the nucleus into the 
cytoplasm. 
 
nef/Nef Early Yes Negative regulatory factor. Down regulates 
CD4 and MHC class I and class II. 
 
vpr/Vpr Late Yes Viral protein r. Causes G2/M arrest, thus 
preventing cell division. Vpr is also involved 
in the import of the pre-integration complex 
(PIC) into the nucleus. 
 
vpu/Vpu Late No Viral protein u. Promotes degradation of 
CD4 in ER and enhances release of virions 
from the plasma membrane. 
 
vif/Vif Late Yes The virion infectivity factor. It inhibits the 
antiviral APOBEC protein and thus G-to-A 
hypermutations. 
 
 
2.2.2  Replication 
The virus particle infects cells by gp120 binding to the primary receptor, the CD4 
molecule, on the target cell (Figure 5). The CD4 receptor is present on CD4+ T-
lymphocytes, macrophages, monocytes, dendritic cells and microglia cells in the 
central nervous system [23, 24].  After binding, gp120 undergoes conformational 
changes that enable interaction with the coreceptor, most often CCR5 or CXCR4 
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[25], see part 2.4.4 below. Binding to the coreceptor brings the virion in close 
contact to the cellular membrane, allowing a part of gp41 to penetrate the cell 
membrane. This penetration mediates fusion of the virus envelope with the cell 
membrane and release of the viral nucleocapsid into the cytoplasm. The RT 
enzyme present in the nucleocapsid converts ssRNA into dsDNA, inside the 
partially opened capsid. Reverse transcription is primed with a human transfer 
RNA (tRNA) that is bound to the viral RNA inside the virion. Although HIV carries 
two strands of RNA only one DNA molecule is formed per virion [26]. One of the 
two copies of ssRNA is thought to act as an alternative template for reverse 
transcription if the RT encounters a nick or break during reverse transcription 
[27]. The ribonuclease H (RNase H) domain of the HIV polymerase degrades the 
viral RNA after reverse transcription. During the transcription, parts of the long 
terminal repeats (LTRs) are generated in the 5’- and 3’-ends of the genome. These 
LTRs are important for the integration process and for transcription and 
translation. The pre-integration complex (PIC) is subsequently transported into 
the nucleus, where the HIV integrase catalyzes the integration of the viral dsDNA 
into the host genome. The integration preferably takes place into active and thus 
open regions of the human genome [28], but integration can also take place in 
resting cells [29-32]. Once integrated the viral DNA is referred to as a provirus 
that remains permanently associated with the host genome. The provirus can 
remain in a latent state (and be passed on to daughter cells by cell division) or be 
activated and transcribed into viral mRNA by the host RNA polymerase II.  
 
 
 
Figure 5. The replication cycle of HIV-1. HIV-1 enters target cell through interactions with CD4 and 
a coreceptor. The RNA is reverse transcribed and inserted into the host cell genome. Transcription 
and translation is performed by the cellular machinery. New viral particles are assembled at the 
plasma membrane. After budding the viral protease cleaves the Gag-Pol precursor polyproteins 
into functional proteins, which generates a mature infectious virus particle. Adapted from [33].  
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A single promotor in the 5’ LTR region mediates transcription of the HIV-1 
genome. The LTR region contains binding sites for several transcription factors. 
Expression from the 5’ LTR generates a 9-kb primary transcript that has the 
potential to encode all nine HIV genes. The primary transcript can be spliced into 
several mRNA species or packed without further modification into new virion 
particles. The early fully spliced transcripts encode the Nef, Tat and Rev proteins 
in a Rev-independent manner. The Tat protein interacts with the transactivation 
response element (TAR), located downstream of the LTR region, to greatly 
increase the levels of transcription of viral RNAs. Thus the Tat protein plays a key 
role in the activation and maintenance of high levels of transcription from proviral 
DNA [34, 35]. The Rev protein binds to the rev responsive element (RRE) in the 
env region of the HIV mRNA and functions as a carrier of the unspliced or partially 
spliced RNA from the nucleus to the cytoplasm.  
 
The late transcription involves expression of the longer gag, gag-pol, env, vif, vpr 
and vpu mRNAs, which are unspliced or incompletely spliced and therefore 
require Rev in order to be transported to the cytoplasm. All mRNAs are translated 
in the cytoplasm near the endoplasmatic reticulum (ER) by the normal cellular 
transcription machinery. The envelope protein (gp160) is processed in the ER and 
the Golgi complex, where it is cleaved by cellular proteases into the surface 
proteins gp41 and gp120 and heavily glycosylated. Finally, gp41 and gp120 are 
transported to the plasma membrane of the cell. 
 
The assembly of new HIV particles begins at the plasma membrane. Two HIV 
ssRNA molecules together with Gag (p55) poly-protein, Gag-Pol (p160), Vif and 
Vpr associates as the virion begins budding from the host cell. Vpu has not been 
detected in virus particles [36]. The accessory protein Vif counteracts the antiviral 
activity of apolipoprotein B mRNA editing enzyme-catalytic polypeptide-like 3G 
(APOBEC3G), by facilitating its degradation and thus prevents its virion 
encapsidation [37, 38]. APOBEC3G contributes to an innate resistance to 
retrovirus infection by deamination of cytidine (C) to uridine (U) in minus strand 
reverse transcripts, a process that results in guanosine (G) to adenosine (A) 
mutation of the plus strand DNA [39]. Hypermutation usually results in the 
production of replication-incompetent virus due to the introduction of stop 
codons. The A-rich genome of HIV is believed to partly be due to the activity of 
APOBEC3G.  
 
The immature HIV-1 particle buds from the cell, but has poor ability to fuse with 
targets cells because of an interaction between Gag and a cytoplasmic tail of 
gp41[40]. After budding, the viral PR cleaves the Gag structural polyprotein 
precursor into matrix (MA), capsid (CA), nucleocapsid (NC) and p6 proteins [41]. 
These proteins form the mature nucleocapsid and matrix, making the virus 
particle infectious [42]. The viral protease also cleaves the Gag-Pol polyprotein 
into the viral enzymes: PR, IN and RT.  
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2.3 HIV GENETIC VARIATION  
2.3.1 Sources of genetic variation 
HIV is one of the fastest evolving organisms known. Due to the fast evolutionary 
rate, the virus evades the host immune system and has the capacity to develop 
resistance to antiretroviral drugs during suboptimal treatment. There are at least 
six mechanisms that contribute to the high genetic variation of HIV:  
 
I) The error-prone RT enzyme generates on average 0.1-0.3 mutations 
per genome and replication cycle [43-45] and it is considered to 
account for most of the point mutations seen in HIV-1. These 
mutations remain uncorrected since RT lacks proofreading activity.   
II) The RT enzyme switches between the two ssRNA strands during 
reverse transcription and it has been estimated that such 
recombination events occur between 2 to 30 times per replication 
cycle [46-48]. For recombination to contribute to evolution the 
template switching needs to result in a novel genetic variant, which 
only happens when the two strands in the infecting virus are different. 
This is referred to as effective recombination rate. The effective 
recombination rate has been estimated to be 1.4±0.6×10−5 
recombinations per site and generation, which assumes a probability 
of coinfection of about 10% [49]. 
III) HIV-1 establishes a lifelong infection with continuous replication and 
high viral production rate. In untreated patients approximately 1010 
new virions are produced every day. These virions have an average 
life-span of 2-3 days [50-52].   
IV) The immune system exerts a high selective pressure on the viral 
population [53, 54]. Therefore, immune-escape variants often have a 
survival advantage and become subject to positive Darwinian 
selection.   
V) The cellular RNA polymerase II, which transcribes the integrated 
proviral DNA into mRNA, is also error-prone due to a lack of 
proofreading activity.  
VI) Finally, the effect of the cellular enzyme APOBEC3G, may (if not 
completely inhibited by Vif) result in excess G-to-A mutations. 
However, viruses with hypermutations resulting in stop codons are 
nonviable and do not contribute to evolution.   
 
The reason why certain mutations survive to the next generation and eventually 
becomes fixed in the population is dependent on a combination of selective 
pressures, fitness costs and chance events.  
 
2.3.2 Genetic variants of HIV 
The high genetic variability of HIV-1 has a direct effect on within-patient 
evolution. In a patient HIV-1 variants can differ by more than 5%, which is a 
greater genetic distance than between the human and the mouse genomes. In 
addition, the high genetic variability of HIV has given rise to series of 
phylogenetically defined groups and clades (subtypes), seen on the population 
level. To date, HIV-1 is divided into three groups, group M (main), O (outlier) and 
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N (non-M non-O) (Figure 1), which probably represent independent transmission 
events from chimpanzees. In 2006, SIV was discovered among the western 
lowland gorillas (Gorilla gorilla gorilla) and the virus was genetically linked to 
HIV-1 group O and the not yet formally approved fourth group, group P.  However, 
chimpanzees are thought to be the original reservoir for SIVgor as well [55]. HIV-1 
group M has successfully spread to all continents on earth and is further divided 
into nine subtypes (A, B, C, D, F, G, H, J and K) [56]. In addition, more that 50 
circulating recombinant forms (CRFs) have been recognized so far 
(http://www.hiv.lanl.gov). The CRFs are recombinant viruses which have been 
formed in patients infected with more than one subtype. The HIV subtypes and 
CRFs have spread unevenly around the world. The highest diversity of HIV 
remains in the western part of Africa and despite the potential for divergent 
viruses to spread only a few subtypes have successfully expanded. About 90% of 
the epidemic comprises of four subtypes (A, B, C and D) and two circulating 
recombinant forms (CRFs) (CRF01_AE and CRF02_AG) [57]. HIV-2 is divided into 
group A and B, which both are endemic in West Africa. In contrast to HIV-1, HIV-2 
have had limited spread to other parts of the world. Founder effects, whereby a 
single chance introduction into a naïve population causes massive spread 
probably account for most of the current geographic distribution of HIV genetic 
variants, but human genetics, behavioral factors and possibly viral fitness 
differences may also have contributed.  
 
2.3.3 Methods to study HIV genetic variation 
Genetic variation and the relationship between sequences can be visualized in a 
phylogenetic tree. It can be used to study evolutionary relatedness of different 
organisms or relationship between strains of the same organism. Due to the fast 
evolution of the HIV virus, it is possible to use phylogenetic trees for detailed 
evolutionary and epidemiological studies. The branching-pattern of the tree is 
called the topology and the length of the branches describes their genetic 
distances, which is related to their evolutionary time. The sequences represented 
by the tips are called taxa. There are several different methods to infer a 
phylogenetic tree. The four main methods are: Neighbor joining, Parsimony, 
Maximum likelihood and Bayesian inference (reviewed in [58]). These methods 
are briefly described in table 2. 
 
To infer a phylogenetic tree the model of sequence evolution (substitution model) 
first needs to be selected. One of the simplest models assumes that all nucleotides 
occur with the same frequency and that all point mutations occur at the same rate. 
However, since the evolutionary process often is more complex, this method most 
often underestimates genetic changes. For instance, transitions are usually more 
common than transversions. Several different substitution models have been 
proposed to more realistically describe sequence evolution by accounting for 
unbalanced base composition and mutation rates. The most complex substitution 
model is GTR (general time-reversible) model, in which each pair of nucleotide 
substitutions has different rates, i.e. it assumes a time reversible symmetric 
substitution matrix in which A is substituted by T with the same rate as T 
substitutes to A. Mutations rates usually also differ across sites of the genome. 
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There exist several methods to account for these rate variations. The most 
commonly used adds a gamma-distributed rate parameter (G) to the substitutions 
model. Furthermore, information about invariant sites (I), can also be added to the 
model. Thus, GTR+G+I represents a complex model that often recapitulates HIV-1 
evolution fairly realistically. To accurately infer a phylogenetic tree the best-fit 
substitution model, G and I should be estimated from the data. In general, the 
simplest model that adequately explains the data should be used. Several 
programs can be used to obtain the best-fit model, such as jModelTest [59] or 
FindModel (http://www.hiv.lanl.gov/content/sequence/findmodel/findmodel.html). 
 
Table 2. Description of phylogenetic methods 
 
Method  
 
 
Description 
 
Advantages  
 
Disadvantages 
 
Examples of 
Software 
 
Neighbor 
joining 
(NJ) 
Creates a pair-wise 
distance matrix 
describing the 
evolutionary distance 
between sequences, 
which is used to 
construct the tree. 
 
Fast; Works well on 
closely related 
sequences. 
Information is lost 
by compressing 
sequences into 
distances. Does 
not explore many 
tree options. 
MEGA  
[60] 
PAUP* 
 
Parsimony Chooses between trees 
to find the one with the 
least number of 
mutations that 
describes the data.  
 
Relatively fast; 
Works well on 
closely related 
sequences.  
Can perform 
poorly if the 
distances between 
sequences varies.  
PAUP* 
MEGA  
[60] 
 
Maximum 
likelihood 
(ML) 
Uses a statistical model 
to find the tree that has 
the highest likelihood of 
producing the observed 
data given the 
assumptions. 
 
More accurate than 
NJ and Parsimony 
on distantly related 
sequences and/or 
rapidly evolving 
organisms. 
Explores a large 
tree space. 
 
High 
computational 
burden. 
PAUP* 
Phylip 
PhyML [61] 
Bayesian 
inference 
Based on a statistical 
model. Simultaneously 
estimates trees and 
uncertainty for every 
branch. 
More accurate than 
NJ and Parsimony 
on distant 
sequences and/or 
rapidly evolving 
organisms. 
Explores a large 
tree space and 
outputs a collection 
of trees that fit the 
data. 
 
High 
computational 
burden; The prior 
distributions for 
parameters needs 
to be specified.  
MrBayes 
Beast 
     
There are different ways of assessing confidence of the branches in the tree. The 
traditional method is called bootstrap analysis, where the original alignment is 
randomly re-sampled with replacement to produce pseudo-replicate data-sets. 
New trees are inferred on these datasets and offer measurements of which part of 
the tree has higher or lower support. The main drawback of bootstrapping is the 
 12 
computational burden, since the original analysis is repeated for each pseudo-
replicate dataset [58], i.e. at least 100 and often to 1000 times. There are other 
alternatives of assessing confidence of the tree topology such as the approximate 
likelihood-ratio test (aLTR) where the significance of a branch is tested based on 
the null hypothesis corresponding to the assumption that the inferred branch has 
length 0 [62]. Moreover, Bayesian methods have assessment of confidence 
naturally implemented in the methodology. It is important to note that a tree is 
the best attempt to explain the data given the model, which is not necessarily the 
same as the evolutionary history.  
  
 
2.4  HIV INFECTION 
2.4.1 HIV-1 transmission 
Globally, sexual transmission accounts for approximately 80% of all HIV 
infections, where heterosexual intercourse accounts for the majority of 
transmissions [18]. The risk of transmission of HIV-1 is 0.01-0.23% after a single 
heterosexual exposure. Higher viral load and genital ulceration are important 
determinants of HIV-1 transmission per coital act [63]. Transmissions can also 
occur by transfer of contaminated blood through needle stick injuries, the sharing 
of contaminated needles between intravenous drug users or from mother to child 
during pregnancy, in utero, during delivery or postnatal through breastfeeding.  
 
Infectiousness is correlated to the viral load and therefore is especially high 
during primary infection when the viral load temporarily is very high. 
Antiretoviral treatment dramatically lowers viral load and several studies have 
demonstrating its potential for prevention of HIV transmission [64-66]. 
 
Several studies have shown that the HIV-1 diversity is low during primary HIV 
infection (PHI) [67-71] and that most HIV-1 infections probably are established by 
one or a few virus particles [70, 72, 73]. However it is still uncertain if more virus 
particles actually are transmitted but only one or a few viruses grows out. 
Transmission bottlenecks have been seen not only in mucosal transmission, but 
also in infections through intravenous drug use [74]. The diversity has been 
shown to gradually increase during the course of infection in the absence of 
treatment [75-77]. However, the diversity has been suggested to decrease in late 
infection [78]. Furthermore, a reduction in evolutionary rate has been shown to 
coincide with disease progression [79]. 
  
 
2.4.2 HIV-1 infection and pathogenesis 
The course of HIV-1 infection can be divided into three stages: the acute stage, the 
chronic stage and AIDS. Immediately after exposure and transmission, the virus 
cannot be detected in plasma. This so called eclipse phase generally lasts 7 to 21 
days [70, 80, 81]. The reason for this is probably that HIV-1 replicates in the 
mucosa, submucosa and draining lymphoreticular tissues (such as gut-associated 
lymphoid tissue). Ones HIV-1 reaches a concentration of 20 copies per milliliter in 
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plasma it can be detected by quantitative clinical assays. Studies implicate that 
CD4+ T-lymphocytes and Langerhans’ cells are the first targets of the virus [82, 83] 
and that monocyte-derived macrophages are generally poor targets as compared 
with CD4+ T-lymphocytes [73]. Studies have shown that HIV-1 rapidly replicates, 
first in the gut-associated lymphoid tissue and then systemically [84], resulting in 
a rapid increasing plasma viral loads to 107 – 108 RNA copies per milliliter at peak 
viremia, which occurs approximately 25 days after infection [81]. In the gut-
associated lymphoid tissue the phenotype of the most productively infected cells 
appears to be the resting CD4+ T-lymphocytes that lack activation markers and 
expressing low levels of the chemokine receptor CCR5 [85]. Instead, many of these 
cells express the α4β7 integrin receptor [86]. Regardless of the route of 
transmission an irreversible destruction of reservoirs of helper T-lymphocytes, 
especially in the gut-associated lymphoid tissue, is seen which has implications on 
the pathogenesis of HIV infection.  
  
The acute phase, which also is called primary HIV infection (PHI) is characterized 
by high viral loads and the sequential appearance of viral markers and antibodies 
in the blood. Approximately, 50% of patients infected with HIV will develop 
symptoms of acute HIV infection. Early HIV infection can be divided into stages, 
called Fiebig stages [81], based on the detection of HIV-1 antigens and HIV-1-
specific antibodies in diagnostic assays (Figure 6). The acute infection phase is 
divided into five Fiebig stages (I-V) and the early chronic HIV infection is defined 
as Fiebig stage VI, occurring at approximately 100 days following infection.  
 
 
Figure 6. Early HIV-1 infection. The first weeks after infection are divided into Fiebig stages that 
are defined by a stepwise gain in positivity for the detection of HIV-1 antigens and HIV-1-specific 
antibodies in diagnostic assays. Adapted from [87]. 
 
The chronic phase is characterized by the establishment of a viral setpoint and 
partial restoration of CD4+ T-lymphocyte levels. The setpoint has been shown to 
be predictive of disease progression in HIV-1 infection as individuals with high 
plasma HIV-1 RNA levels progress more rapidly to AIDS than those with low levels 
[88]. The average viral setpoint is around 30,000 HIV-1 RNA copies per milliliter 
plasma in HIV-1 infected patients, which is a level that has been suggested to 
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maximize the transmission potential by mathematical modeling [89]. In the 
absence of treatment the average time to onset of AIDS is around 10 years [90]. 
AIDS results from long-term (chronic) HIV infection, where the immune system 
has been exhausted by the constant battle of the infection, and specific 
opportunistic infections or malignancies are diagnosed. In addition, in the US an 
absolute CD4 cell count of less than 200 cells/µl also constitutes an AIDS criterion.  
 
Some patients remain asymptomatic for more than 10-15 years and are called 
long-term non-progressors. Many of these patients have certain genetic traits, 
especially certain HLA types (e.g. HLA B57 and HLA B27), which have been 
associated with delayed HIV-1 escape and a decreased rate of disease progression. 
In contrast, there are other HLA types that are associated with an increased rate of 
disease progression (e.g. B35-Px), where patients progress to AIDS within 2-3 
years [91]. The delta-32 deletion in the CCR5 gene (CCR5Δ32) is another genetic 
trait that either causes high resistance to infection or delay disease progression, 
when present homozygous or heterozygous, respectively [92, 93].  
  
2.4.3 Immune responses against HIV-1 
The first line of defense in response to HIV-1 infection is the innate immune 
system, followed by the development of adaptive immune responses. The initial 
decline of plasma viral load after peak viremia during acute infection is thought to 
be due to mainly CD8+ T-lymphocyte-mediated killing of productively infected 
cells [94, 95]. Thus, HIV-1 specific T cell responses develop before seroconversion 
and just before the peak viremia is reached. However, HIV usually rapidly escapes 
these first T cell responses, indicating that many targeted epitopes are readily 
changeable. T cell responses targeting more slowly evolving or conserved 
epitopes develops later. These later T cell responses may be important in lowering 
and maintaining the viral set-point [94].     
 
Antibodies directed against HIV-1 have been seen to arise within eight days of 
infection. These first antibodies forms immune complexes and are not likely to 
impact on the control of acute phase viremia, however early escape from 
neutralizing antibodies has been reported [96-98]. No association has been seen 
between specific antibody responses and natural control of HIV-1 viremia during 
chronic infection. Before onset of late HIV-1 infection, the humoral immune 
system constantly changes specificity to target new HIV-1 variants. Even though 
some of these antibodies may be neutralizing they lag behind, rarely targeting the 
contemporary viruses [54, 98-100].  
 
2.4.4 Coreceptor use 
The entry of HIV-1 into target cells is dependent on the binding of the viral 
envelope glycoprotein to its receptor CD4 and a coreceptor, most often C-C 
chemokine receptor type 5 (CCR5) or C-X-C motif receptor 4 (CXCR4) (Figure 7) 
[101-105]. Several additional co-receptors have been identified in vitro, but only 
the CCR5 and CXCR4 appear to have a major role in HIV-1 attachment in vivo 
[106]. Some viruses can use both CCR5 and CXCR4 coreceptor (R5X4-viruses). 
R5X4 viruses are also called dual/mixed to signify that some assays do not 
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distinguish between viruses consisting of truly dual tropic clones and those with 
mixtures of R5 and X4 clones [77]. Although CXCR4-using viruses (X4-virus) have 
been shown to be transmissible [107], the majority of infections are established 
by CCR5 using viruses (R5-virus). During transmission only one or a few viral 
particles establish the infection even though the inoculum most probably contains 
more virus variants. One theory suggests that this transmission bottlenecks is the 
result of selection acting on the envelope gene, which favors CCR5-using viruses 
during transmission and/or establishment of successful infection [67, 68, 108]. 
Indeed, individuals homozygous for the delta-32 deletion in the CCR5-gene seem 
to be protected against HIV-1 infection. However other studies have argued that 
there is no conclusive evidence to support that CXCR4 using variants are less 
transmissible [77, 109]. In about 50-70% of HIV-1 infected patients the viral 
population switches to include X4-virus later in infection [77, 110-112]. The 
emergence of X4-virus is temporally associated with accelerated CD4+ T-
lymphocyte decline and progression to AIDS [77, 110, 111, 113, 114]. This 
pathogenic difference was known already in the late 1980’s, before the 
coreceptors were identified. At that time, the replicative capacity of HIV-1 variants 
in peripheral blood mononuclear cells (PBMC) was referred to as rapid/high or 
slow/low [115, 116], and the capacity of inducing syncytia in PBMC or MT-2 cells 
was identified (referred to as syncytium inducing (SI) and non-syncytium 
inducing (NSI)) [117-120]. About a decade later the coreceptors were identified 
[101-105] and since then there has been intense research to try to understand the 
complex mechanisms behind coreceptor switch. However, it is still not known if 
the emergence of X4-viruses is a cause and/or a consequence of 
immunodeficiency [121]. 
 
 
 
Figure 7. Schematic illustration of HIV-1 entry into target cell. Gp120 binds to CD4, which induces 
conformational changes in gp120 and exposure of the coreceptor binding site. Conformational 
changes in gp41allows insertion of the fusion peptide into the host cell membrane. During the final 
step the six-helix bundle is formed, which brings the viral membrane and the host membrane 
together and allows fusion. (Kindly provided by Dr R.W Doms).  
 
The CXCR4 receptor is mainly expressed on naïve CD4+ T-lymphocytes, whereas 
memory CD4+ T-lymphocytes mainly expresses CCR5. Since the CCR5 receptor is 
also expressed on macrophages it was first believed that R5-viruses were 
macrophage-tropic (M-tropic) and that X4-viruses were T-lymphocyte tropic (T-
tropic). However, it has been shown that monocyte-derived macrophages are 
generally poor targets for primary HIV-1 isolates as compared to CD4+ T-
lymphocytes [73]. Thus, both R5 and X4 virus are mainly CD4+ T-lymphocyte 
tropic. 
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The CCR5 and CXCR4 coreceptors are chemokine receptors that belong to the 
seven transmembrane spanning G-protein-coupled receptors that are involved in 
signal transduction [122, 123]. The natural ligands (chemokines) for CCR5 are 
RANTES (regulated on activation, normal T-cell expressed, and secreted), 
macrophage inflammatory protein (MIP) -1  and MIP- 1 . For CXCR4 the natural 
ligand is stromal cell-derived factor 1 (SDF-1). These chemokines exhibit 
suppressive effect on HIV-1 by down regulating coreceptor expression and by 
competitive binging [124, 125]. In addition, individuals with the CCR5Δ32 are 
protected against HIV-1 infection with R5-viruses (which establish most new 
infections). Thus, the development of the drug maraviroc, which blocks the CCR5 
coreceptor, was a quite logic step to inhibit HIV-1 replication (se section 2.5.1 
about antiretroviral treatment).  
 
The viral envelope proteins gp41 and gp120 are glycosylated in the endoplasmatic 
reticulum where they are produced. The surface of gp120 consists of five constant 
regions (C1-C5) and five variable regions (V1-V5). The principal determinant of 
coreceptor use is the variable loop 3 (V3) [126], but parts of V1/V2, V4 and C4 
have also been shown to impact coreceptor use [127-129]. Both the CD4 binding 
site and the co-receptor binding site are partly masked by the hypervariable 
V1/V2 loop structure. Attachment between gp120 and the CD4 molecule displaces 
the V1/V2 loop and V3, creating the coreceptor binding site [130, 131]. The V3 
loop is a 35 amino acid long loop structure held together by a disulphide bond 
between the cysteins at position 1 and 35. It has been shown that a few amino acid 
changes in V3 can change the coreceptor use from CCR5 to CXCR4 [132, 133]. 
Electrostatic interactions have a major role in coreceptor binding [134]. Thus, the 
presence of basic amino acids (lysine or arginine) at positions 11 and 25 is 
associated with CXCR4 use [133], whereas acidic or uncharged amino acid in 
position 11, 25 or 28/29, resulting in a low V3 charge is associated with CCR5 use 
[133, 135, 136]. Moreover, the V3 charge increased with time in R5 populations 
from patients with virus populations that switch coreceptor use, while it remains 
unchanged or decreased in non-switch populations[137]. Glycosylation of the 
envelope spikes have been shown to be important for the folding of gp120 upon 
binding as well as determinants of the coreceptor usage of HIV-1 [138, 139]. In 
addition, this host derived glycan-shield hinders efficient antibody binding, thus 
impairing immune recognition. During the course of infection, the glycosylation 
sites in the HIV-1 envelope gene continuously changes leading to an evolving 
glycan-shield [99]. In contrast, during primary infection the level of glycosylation 
of the envelope spikes has been shown to be lower [140].  
 
2.4.5 Tropism testing 
Coreceptor tropism refers to the ability of HIV-1 to enter CD4 cells by the CCR5, 
CXCR4 or both coreceptors (dual tropism) [141]. Viral tropism can be assessed by 
genotypic or phenotypic approaches. The first widely used phenotypic method 
was the MT-2 assay. In this assay patient-derived cells or established isolates are 
co-cultured with MT-2 cells, which express CXCR4 coreceptor but not the CCR5 
coreceptor [142]. X4 and dual-tropic R5X4 viruses are capable of infecting the MT-
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2 cells which results in the formation of large syncytia that are visible by light 
microscopy. The viral replication can also be assessed by detection of viral antigen 
in culture supernatant. The main drawback of this assay is that no negative 
control is used. Thus, if a virus does not grow in the MT-2 assay, it might be due to 
technical difficulties that prevent infection or because it is a R5 virus. A second 
drawback is that it is labor intensive and requires viral culturing in a BSL3 facility 
and a third drawback is that it typically tests PBMC virus rather than plasma virus.  
 
Today, recombinant phenotypic assays are available, such as the Trofile assay 
[143]. In this assay, the entire patient-derived env gene is amplified directly from 
plasma by PCR and inserted into an expression vector. This vector and a 
replication-defective proviral vector containing a luciferase reporter gene are co-
transfected in a HEK293 cell line to produce a pseudovirus population, which is 
subsequently used to infect U87 cell lines expressing either CXCR4 or CCR5 
receptor. Infection is assessed by quantifiable light emission. Co-receptor 
antagonists are added as additional controls. The reliability of this assay depends 
mainly on the sensitivity and accuracy of the cDNA synthesis and PCR and 
proportion of HIV-1 population amplified. The assay can be used with plasma HIV-
1 RNA loads greater than 1000 copies per milliliter and X4 variants that comprise 
0.3% of the population can be detected with 100% sensitivity [144]. The test can 
be done on both RNA and DNA but in Europe the commercial test is available only 
for plasma RNA. Other similar assays exists, such as the Toulouse Tropism Test 
[145], however insufficient data exist to assess the reliability of this assay for 
samples with low viral loads.  
 
Genotypic tropism testing is based on sequencing of the V3 region of the HIV-1 env 
gene directly from patients plasma samples [146-148]. Either population based 
sequencing (Sanger sequencing) or ultra-deep pyrosequencing (UDPS) 
approaches have been used for both viral RNA and DNA. The phenotypes of the 
sequences are predicted by bioinformatic interpretation techniques, such as 
11/25 charge rule, the position-specific scoring matrix (PSSM) and geno2pheno 
(G2P). Briefly, the 11/25 charge rule is the simplest algorithm, which takes only 
the charge of the amino acids at key position 11 and 25 in the V3 loop into 
account. In comparative studies, only a moderate correlation with results from the 
original Trofile assay was reported.  
 
PSSM is a more advanced method, where the sequences’ likelihood of being 
derived from an X4 virus for every possible amino acid at every individual 
position is calculated [149].  There are two matrices available for determining 
scores in subtype B: i) X4R5, which is calculated using sequences with known 
coreceptor phenotype as indicated by growth on indicator cells expressing CD4 
and either CCR5 or CXCR4. ii) SINSI, is calculated using sequences producing 
syncytium on the MT2 cell line. In either case, the input sequences are compared 
and aligned to sequences of known coreceptor use (e.g. X4). The better the fit, 
the higher PSSM score and the higher the score the higher likelihood that the 
sequence fragment has X4 properties. Sequences with values above -2.88 are 
considered X4, whereas sequences with scores below -6.96 are considered R5. 
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Sequences with intermediate scores cannot be predicted using this method. This 
method can be accessed online: http://indra.mullins.microbiol.washington.edu/ 
webpssm/ 
 
Another advanced prediction method is G2P[coreceptor] [150]. This method is based 
on a statistical learning method called a support vector machine which is trained 
with a set of nucleotide sequences that corresponds to R5, dual/mixed tropism or 
X4 phenotypes. Nucleotide sequences are used as input. The result of 
interpretation is given as a false positive rate (FPR), which is defined as the 
probability of falsely classify an R5 virus as X4. The European guidelines on the 
clinical management of HIV-1 tropism testing recommend that a FPR of 5.75% 
should be used [151]. This method can be accessed online at: 
http://coreceptor.bioinf.mpi-inf.mpg.de/index.php. 
 
None of the available genotypic prediction methods take additional regions of env, 
outside the V3 loop into account. This means that sites that might be important in 
e.g. V1/V2 are missed. PSSM and G2P have been evaluated in several studies and 
clinical trials. In a study published by Harrigan et al., these methods were 
compared with the original Trofile assay. The sensitivities were 56 and 63% and 
specificities were 90 and 91% for the two assays, respectively [152]. Indeed, it is 
important to note the concordance between phenotypic and genotypic methods is 
not perfect [107, 153, 154] and quite commonly the genotypic prediction tools 
falsely predict R5 variants as X4 variants [107]. These rates of false positives 
might not be a problem when screening prior to maraviroc use, especially if other 
treatment options exists, however when searching for rare cases of X4 variants 
(e.g. X4/X4R5 transmission) in UDPS studies, the predictions needs to be 
interpreted with caution [109]. 
 
 
2.5  ANTIRETORVIRAL TREATMENT AND RESISTANCE 
2.5.1 Antiretroviral treatment 
Without the use of antiretroviral treatment, almost all HIV-1 infected patients 
would die from AIDS. In 1987, the first drug for HIV treatment was approved. It 
was zidovudine (AZT), a nucleoside reverse transcriptase inhibitor (NRTI) that 
interferes with HIV replication by competitively inhibiting the reverse 
transcriptase enzyme, resulting in chain termination during viral DNA synthesis 
[155, 156]. In the 1990’s additional NRTIs, non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) became available (Table 2). However, HIV quickly developed 
resistance to these drugs since they were used in mono- or dual therapy regimens. 
It was not until 1996 when drugs from at least two different drug classes, NRTIs, 
NNRTIs and protease inhibitors (PIs), were used in triple combination, called 
highly active antiretroviral therapy (HAART) or combination antiretroviral 
therapy (cART), that the morbidity and mortality of HIV-1 infected patients were 
greatly reduced [157-159]. Successful HAART dramatically suppresses viral 
replication and reduces the plasma viral load to below limits of detection of the 
most sensitive clinical assays (<20 RNA copies/mL). However, despite HAART low 
levels of free virions can be found in the plasma. Whether this residual viremia 
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represents ongoing cycles of replication [160] or simply the release of virus from 
stable reservoirs [161-166] is controversial. Since no viral evolution has been 
confirmed the later explanation is more likely [167]. 
 
Table 2. Antiretroviral drugs approved by Food and Drug Association (FDA) and 
European Medicines Agency (EMA) 
Drug Approved 
FDA/EMA 
Drug mechanism  
NRTIs   
NRTIs are first activated into the 5’-triphospate form by 
host enzymes. The active NRTIs compete with RT’s natural 
substrates (dNTPs) and when incorporated they function 
as chain terminators, lacking a 3’-hydroxyl group 
necessary for elongation [168].  
abacavir (ABC) 1998/1999 
didanosine (ddI) 1991 * 
emtricitabine (FTC) 2003/2003 
lamivudine (3TC) 1995/1996 
stavudine (d4T) 1994/1996# 
tenofovir (TDF) 2001/2002 
zalcitabine (ddC) 1992 * 
zidovudine (AZT) 1987/1987 
NNRTIs   
NNRTIs inhibit DNA polymerization by binding a small 
hydrophobic pocket near the RT active site, which induces 
a conformation change of the substrate-binding site and 
reduces polymerase activity [169]. 
 
delavirdine (DLV) 1997/- 
efavirenz (EFV) 1998/1999 
etravirine (ETR) 2008/2008 
nevirapine (NVP) 1996/1998 
rilpivirine 2011/2011 
PIs   
Most PIs are peptidic or peptidomimetic compounds 
designed as analogs of the cleavage sites found within the 
Gag and Gag-Pol precursor proteins. Some PIs are 
transition state analogues that resemble the transition 
state of a substrate molecule in the PI catalyzed reaction. 
PIs have poor oral bioavailability and most PIs are thus co-
administrated with low dose ritonavir, an HIV-1 protease 
inhibitor that inhibits the 3A4 isozyme of cytochrome P450 
(CYP 3A4), which is responsible for the metabolism of 
most of these drugs [170].  
Atazanavir (ATV) 2003/2004 
Darunavir  2006/2008 
Fosamprenavir 
(fAMP) 
2003/2004 
Indinavir (IDV) 1996/1996 
Lopinavir (LPV) 2000/2001 
Nelfinavir (NFV) 1997/1998¤ 
Saquinavir (SQV) 1995/1996 
Tipranavir (TPV) 2005/2005 
Fusion inhibitors  Enfuvirtide is a peptide drug selected from chemically 
synthesized peptides derived from various regions of 
gp41 [171]. The peptide sequence binds to gp41, 
preventing the formation of the hairpin structure (six-
helix bundle) and consequently, the fusion [172]. It is 
sensitive to proteolytic digestion and needs to be 
administered by injection. 
Enfuvirtide (T-20) 2003/2003 
Entry inhibitors  Maraviroc is a noncompetitive, specific, slowly reversible 
CCR5 coreceptor antagonist that selectively binds to the 
human chemokine receptor CCR5 present on the host cell 
membrane. Binding alters the conformation of the 
receptor and prevents interaction with the V3 loop to 
CCR5, and the subsequent membrane fusion [173, 174]. 
HIV-1 tropism test such as the Trofile assay is 
recommended before use.  
Maraviroc (MVC) 2007/2007 
Integrase inhibitors  The integrase inhibitor binds to the specific complex 
between integrase and the viral DNA and thus selectively 
targets the strand transfer reaction of the integration 
reaction [175, 176]. 
Raltegravir (RAL) 2007/2007 
*withdrawn from market by manufacturer. #not recommended by Swedish guidelines due to side 
effects. ¤not recommended by Swedish guidelines due to low antiviral activity. 
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HAART reduces the rate of sexual transmission, which has additional public health 
benefits [64].  However, HAART alone cannot eliminate HIV-1 infection since virus 
is hidden in the latent reservoirs [177]. Viral reservoirs have been found in a 
variety of cell types including CD4+ T-lymphocytes [177, 178], dendritic cells 
(DCs) [179-181] and macrophages [178]. Resting memory CD4+ T-lymphocytes 
decay very slowly during HAART, with an average half-life of 44 months, 
indicating that under current treatments it will take over 60 years to deplete this 
reservoir [182]. Therefore, HIV infected patients cannot be cured from the 
infection by current treatment options.  
 
In the beginning of 21st century three new drug classes were introduced: fusion 
inhibitors, entry inhibitors and integrase inhibitors (Table 2). In the western 
world, where HAART is affordable, HIV infection has turned from a deadly 
infection into a chronic life-long disease. However, in the developing world, 
especially in low and middle- income countries about 53% of eligible HIV infected 
patients have not yet started HAART [20].  
 
2.5.2 Monitoring of treatment  
Disease progression is monitored by CD4 cell counts, HIV-1 plasma RNA levels and 
clinical symptoms. In untreated patients, CD4 cell counts is the most important 
marker, while treated patients are primarily monitored by measuring HIV-1 RNA 
levels in plasma. HIV-1 treatment guidelines in the US and European Union 
recommend the initiation of HAART when the CD4 cells in peripheral blood 
decline to 350 cells per μL. The recommended first line HAART regimen, consists 
of two NRTIs and either a NNRTI or a PI, and are quite similar in the US [183] and 
in Europe [184]. The Swedish guidelines are summarized in Table 3 [185]. 
Combination regimens consisting of raltegravir and two NRTIs are also 
recommended as initial regimens in the US and European guidelines, but not in 
the Swedish guidelines.  
 
Table 3 
Preferred 1st line regimen* Drugs 
NNRTI-based efavirenz + abacavir/lamivudine or tenofovir/emtricitabin 
PI-based atazanavir/r + abacavir/lamivudine or tenofovir/emtricitabin 
durunavir/r + abacavir/lamivudine or tenofovir/emtricitabin 
* Swedish guidelines for antiretroviral therapy (www.smittskyddsinstitutet.se/rav) [185]. 
 
2.5.3 Treatment failure 
Treatment failure of HAART naïve patients can be caused by several factors, 
including poor adherence, pharmacologic factors such as drug-drug interactions 
that impair absorption or accelerate clearance, host factors (e.g. low CD4+ cell 
count at start of therapy), transmitted drug resistance or drug resistance 
development during treatment [186]. There are three types of treatment failure: 
virologic failure, immunologic failure and clinical progression. Virologic failure is 
when the viral load rebounds or does not decrease sufficiently despite HAART. 
Immunologic failure is when the CD4+ T-cell counts do not increase despite 
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HAART. Finally, clinical progression is when symptoms of HIV disease occur 
despite HAART.   
 
During suboptimal treatment (e.g. mono or dual drug combinations as well as 
insufficient adherence to HAART) selection of pre-existing variants with reduced 
susceptibility or development of de novo resistance mutations can occur [187]. 
Thus, for an HIV treatment to be successful, patients need to be committed and 
adherent to reduce the possibility of drug resistance development.  
 
2.5.4 Drug resistance 
The drug resistant variants usually have reduced fitness compared to wild-type 
virus. This is especially true for viruses with single primary resistance mutations. 
In contrast, additional mutations, which may evolve over time during continued 
drug selective pressure, may be compensatory, thus restoring fitness to near wild-
type levels. The rate of development of drug resistance depends on patient 
adherence to treatment, the genetic barrier (see below), host genetics, and fitness 
of the drug resistant variant [188, 189]. The emergence of drug resistance has 
been shown to be associated with an increased mortality among patients first 
starting HAART [190]. Thus, the clinical management of HIV-1 infection is 
important to reduce the risk of treatment failure. Genotypic HIV-1 resistance 
testing is an important tool for clinical management HIV-1 infection. Population 
based sequencing of pol gene (including PR, RT and when required also IN) is 
generally generated by in-house methods or by commercial assays such as 
ViroSeq from Abbott. The sequences can be used for online prediction at Stanford 
(http://hivdb.stanford.edu) and National Agency for AIDS Research 
(www.medpocket.com). 
 
The terminology used in the field of drug resistance classification can be confusing 
and no universal system exists. Thus, drug resistance mutations are classified 
differently by different systems, which also change over time. Here, I use the 
definition from the latest update from the International AIDS society - USA [191], 
where PI mutations are classified into major and minor mutations depending on 
when they are selected. Major mutations are defined as those selected first in the 
presence of the drug or those substantially reducing drug susceptibility. Minor 
mutations generally emerge later and do not by themselves have a strong effect on 
phenotype. However, minor mutations may improve fitness of viruses containing 
major drug resistance mutations. NRTI and NNRTI mutations are not classified 
into major and minor mutations by the IAS-US system, instead the first mutations 
that arise are referred to as primary mutations. Furthermore, HIV drugs can be 
divided into low or high genetic barrier to resistance depending on the number of 
mutations needed and the fitness cost of these mutations to the virus. Most NRTIs 
and NNRTIs are generally considered to have low genetic barrier whereas PIs are 
considered high genetic barrier to resistance (Figure 8).  
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Figure 8. The development of drug resistance to low and high genetic barrier drugs. Low genetic 
barrier drugs: Selection of pre-existing minority variants with primary/major mutations. High 
genetic barrier drugs: Selection of primary/major mutations followed by de novo evolution of 
minor mutations. Red: Wild-type virus. Yellow: Primary/major mutations are the first mutations 
that arise and often have a strong effect on resistance and a fitness cost and to e.g. lamivudine 
(3TC), zidovudine (AZT) and PIs. Blue: Minor mutations usually have little or no effect on 
resistance, but restore fitness. Adopted from [21]. 
 
In many cases the drug resistance mutations alters binding site for the nucleoside 
or NRTI, thus preventing incorporation of the drug into the nascent chain. 
Mutations associated with this mechanism include the M184V/I and K65R. The 
M184V/I mutation can emerge with 3TC or FTC therapy [192, 193]. For AZT 
however, the mutations do not prevent the binding and incorporation of AZT 
triphosphate into the growing chain, but rather seem to activate a reverse reaction 
by which the AZT nucleotide is removed from the chain, subsequently permitting 
normal elongation [194]. These mutations are called thymidine analog mutations 
(TAMs) and they promote pyrophosphorolysis and are involved in the excision of 
AZT and d4T [195]. TAM amino acid changes in HIV-1 RT include two distinct 
pathways: the TAM1 pathway (M41L, L210W, T215Y, and occasionally D67N) and 
the TAM2 pathway (D67N, K70R, T215F and 219E/Q) [187, 196].  
 
NNRTI resistance generally result from single amino acid substitutions such as 
K103N and Y181C [197, 198]. Most NNRTI resistance mutations cause some level 
of cross-resistance among different NNRTIs. In contrast to NRTI resistance 
mutations, which often are associated with reduced fitness, single nucleotide 
changes associated with NNRTI resistance can result in high-level resistance with 
only a slight loss of fitness [199, 200]. The low genetic barrier, minimal impact on 
fitness and the slow reversion of NNRTI mutations in patients in the absence of 
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drug contribute to transmission and stability of NNRTI-resistant HIV-1 in the 
population [201]. In HIV-1 group O and HIV-2, the 181C are commonly found as 
wild-type variants [202], thus NNRTIs are ineffective against these viruses. The 
mutations associated with NRTI and NNRTI drug resistance are summarised in 
Figure 9. 
 
 
 
 
Figure 9. Mutations associated with NRTI and NNRTI drug resistance. All mutations associated 
with ETR are not shown. Adapted from [191].  
 
Resistance to PIs was initially expected to be low, because of the vital role of this 
enzyme in the life cycle of HIV-1 and its relatively small size. However, due to the 
plasticity of the protease, drug resistance can develop also to PIs.  PI resistance 
requires a stepwise accumulation of major and minor (compensatory) mutations 
[203] and since several mutations are needed the genetic barrier to resistance is 
higher for PIs compared with NRTIs and NNRTIs (Figure 8). Unlike NNRTI 
resistance mutations, major drug-resistant PI mutations are rarely observed in the 
viral populations in protease naïve individuals. Finally, most PIs share similar 
chemical structure and cross-resistance is commonly observed.  
 
Resistance to integrase inhibitors is almost always associated with mutations 
within the integrase active site [176]. These mutations have deleterious effect on 
the enzymatic function of the enzyme and have high fitness cost to the virus. 
However, development of compensatory mutations will somewhat restore fitness 
[201]. Mutations that confer resistance to the fusion inhibitors T-20 also results in 
reduced replicative fitness, probably because mutations that reduce T-20 binding 
also reduce the efficiency of six-helix bundle formation which is essential for viral 
fusion [172]. The resistance profile towards the entry inhibitor maraviroc is 
different from the other HIV-1 drugs because it binds to a host receptor. 
Resistance to maraviroc can either confer tropism switching, increase affinity to 
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the coreceptor or use of the inhibitor-bound receptor for entry [201]. However, 
evaluations of coreceptor use in clinical trials have shown that a coreceptor switch 
to CXCR4 occurs in patients with pre-existing CXCR4-using virus and does not 
seem to be a favoured resistance pathway [204]. 
 
2.5.5 Minority drug resistance 
Due to the high mutation rate of HIV-1, it has been predicted that drug resistance 
mutations spontaneously develop every day in untreated patients [205]. Thus pre-
existing drug resistance to low genetic barrier drug such as lamivudine and 
nevirapine is likely to be present also in patients that have never received ART 
and not been infected by resistant virus. The clinical relevance of these mutations 
is not yet fully understood.  
 
Recently, several reports indicate that low-frequency or minority drug resistance 
HIV-1 variants have clinical significance. It has been shown that these variants 
adversely affect the response to HAART thus increasing the risk of virological 
failure, especially if mutations associated with resistance to NNRTIs are present 
[206-212]. However, in other studies no association between minority variants 
and virologic failure has been found [213, 214]. Available data suggest that pre-
existing minority resistance mutations may have greater impact on the clinical 
utility of drugs with low genetic barrier than those with high genetic barrier [215, 
216]. These minority resistance mutations are thought to mainly represent 
unrecognised transmitted resistance rather than spontaneous resistance 
mutations due to replication infidelity. In contrast, minority X4 or R5X4 viruses 
may arise spontaneously as a first step towards coreceptor switch and may lead to 
therapy failure to regimens containing maraviroc [217]. It is not known at which 
frequency of X4 virus the maraviroc treatment is still active. Prior to maraviroc 
use the European guidelines [184] and the Swedish guidelines [185] currently 
favor genotypic testing for determining coreceptor use, while the US guidelines 
favor the phenotypic Trofile assay ([183].  
 
2.5.6 Transmitted drug resistance 
Transmitted drug resistance (TDR) is a clinical and epidemiological problem 
because it may reduce the efficacy of antiretroviral treatment. The prevalence of 
TDR ranges from 5.6% in Sweden to 14.6% in the U.S. [218-222]. The level of drug 
resistance in patients infected with a drug resistant founder virus is usually low 
with only one or a few drug resistance mutations, which is somewhat difficult to 
explain because most treated patients have virus with more resistance mutations. 
This could be due to that virus with lower number of drug resistance mutations 
have higher transmission fitness. Another reason could be that the transmitted 
drug resistant virus had more mutations, but that these may have fully or partially 
reverted to wild-type after transmission due to their fitness costs. It has been 
shown that some mutations quickly revert to wild-type (e.g. M184V) while others 
appear to persist for many years (e.g. M41L) [223-226]. These differences most 
likely reflect the combined effect on replicative capacity of the mutations, the 
reversion possibilities and the presence of compensatory mutations [227]. 
Partially reverted mutations may be present as minority mutations, which might 
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be detected with deep sequencing techniques (see section 2.6 on UDPS), even 
though they remain hidden with routine resistance tests that are based on 
population Sanger sequencing. In addition, HIV-1 infects long-lived memory CD4+ 
T-lymphocytes and it is therefore likely that the drug resistant founder variant(s) 
will be stored in these archives along with a representation of all other variants 
that evolve over time in the individual. Furthermore, if the selection pressure 
changes, these archived variants can reappear, which has been shown for both 
wild-type variants and resistant variants [228-231]. The reappearance of resistant 
virus has been associated with treatment failure [230, 231].  
 
 
2.6  DEEP SEQUENCING OF HIV-1 
2.6.1 Next generation sequencing technologies 
Over the past six years new sequence technologies have been developed, which 
have revolutionized genomic science. These technologies are referred to as next 
generation sequencing (NGS) technologies. The population based Sanger method 
[232] is considered as a ‘first generation’ technology, and dominated the 
sequencing field for about two decades prior to the development of NGS [233]. 
The high throughput of the NGS technologies, generating million of sequence 
reads in a short time, makes them suitable for shotgun sequencing of whole 
genomes, such as human, bacteria and plants. In shotgun sequencing, short 
sequence reads are generated from fragmentized DNA. The reads are aligned to a 
known reference sequence or assembled de novo. Sequencing platforms that 
generates short reads and huge amount of data are suitable for such projects (e.g. 
SOLiD and HiSeq). For projects where smaller genomes or fragments are analyzed, 
usually platforms such as 454 sequencing, Ion Torrent or MiSeq are also suitable. 
Most NGS platforms offers the possibility of deep sequencing, where for instance 
rare HIV-1 drug resistance mutations in a background of wild-type variants can be 
analyzed. Due to the length of the reads, 454 sequencing has an advantage for 
deep sequencing projects, referred to as ultra-deep pyrosequencing (UDPS). In 
Table 4, the most commonly used technologies and their pros and cons are 
described.  
 
The NGS technologies described above are constantly improving, generating 
longer and increased throughput. In the last couple of years new NGS technologies 
have been developed, such as Heliscope from Helicos Biosciences and PacBio from 
Pacific Biosciences. The Heliscope and PacBio promises to resolve true single 
molecule sequencing. It is too early to say if these techniques will get a 
marketplace. This will depend on their performance in this highly competitive 
field. It is also likely that the several NGS platforms will coexist in the marketplace, 
due to specific features that makes some more advantageous for specific 
application compared to others [233]. 
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Table  4. NGS technologies 
Sequence 
technology 
Description Read 
length 
(bp) 
Number 
of reads 
per run 
Pros Cons 
Sanger 
sequencing 
Chain termination method with 
dye-labeled dideoxynucleotides. 
Capillary electrophoresis and 
fluorescence detection that 
provides four-color plots to 
reveal the DNA sequence. 
 
1000 96 Population 
based 
sequencing. 
Low error 
rate. 
No high 
throughput. Can 
only detect 
polymorphism 
≥20%. 
454 GS FLX 
titanium and 
454 junior/ 
Roche 
The DNA templates are clonally 
amplified on beads (one 
template/bead) in an emulsion 
based PCR [234].  The beads are 
transferred to a PicoTiterPlate. 
Sequencing chemistry by 
pyrosequencing, where the 
intensity of the bioluminescence 
is recorded and the DNA 
sequence is revealed.  
 
2001 
5002,3 
1 million 
70,0003 
Longer 
reads 
improve 
linkage 
analysis. 
High errors 
frequency in 
homopolymer 
regions. 
MiSeq and 
HiSeq/ 
Illumina 
The DNA templates are clonally 
amplified on a solid plate 
generating clusters [235]. 
Sequencing by reversible 
terminators in a cyclic method 
that comprises nucleotide 
incorporation, fluorescence 
imaging and cleavage.  
 
2 x 1004 600 
million - 
3 billion 
Currently 
dominates 
the NGS 
market for 
shut-gun 
sequencing. 
Time 
consuming 
library 
preparation, 
long run times. 
SOLiD/ Life 
Technologies 
The DNA templates are clonally 
amplified on beads (one 
template/bead) in an emulsion 
based PCR [234]. Sequencing 
chemistry by sequencing by 
ligation of cleavable probes. 
Fluorescence imaging to 
determine the ligated probe. 
 
60 
 
1 - 3 
billion 
2 + 1 base 
encoding 
provides 
inherent 
error 
correction. 
Long run times, 
short reads. 
IonTorrent 
/Life 
Technologies 
The DNA templates are clonally 
amplified on beads (one 
template/bead) in an emulsion 
based PCR [234]. Sequencing 
based on sequencing by 
synthesis technology where 
release of H+ is measured as a 
result of an incorporated 
nucleotide.  
 
100 
200 
1.2 -to 
660 
million 
 
Scalable 
Less labor 
intensive 
compared 
to 454 and 
Illumina. 
High errors 
frequency in 
homopolymer 
regions (similar 
to 454). 
1 454 GS FLX, 2454 GS FLX titanium, 3454 GS Junior System. 4Paired-end sequencing. Adapted from 
[233]. 
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2.6.2 Ultra-deep pyrosequencing (UDPS) 
One application of NGS is deep sequencing, referred to as ultra-deep 
pyrosequencing (UDPS), which is performed on the 454 platform. UDPS allows 
identification of rare genetic variants, which are not detectable by population 
based Sanger sequencing [207, 236-238].  The depth of the UDPS analysis is 
primarily determined by the number of templates that can be successfully 
extracted and amplified from the starting material and by the error rate of PCR 
and UDPS. 
 
Figure 10 schematically describes the different steps in the UDPS technology.  
First the DNA library is prepared, by amplifying the region of interest. The A and B 
adaptor are either synthesised as a part of the PCR primers or subsequently 
ligated to the amplicons. These adaptor sequences are required for binding of the 
amplicons to the beads during the emulsion based PCR (em-PCR) and enables 
bidirectional pyrosequencing. The DNA amplicons are diluted so that statistically 
only one molecule will bind to each bead. The beads are separated into individual 
water droplets in an emulsion, where each water droplet is its’ own PCR reactor, 
which enables each DNA molecule to be clonally-amplified on the bead. The beads 
with bound DNA are enriched and distributed on a titanium coated PicoTiterPlate 
(the titanium coated plates became available in 2008 and increased read length 
and improved quality by reducing crosstalks between adjacent wells), which is a 
fiber optic slide, containing millions of small wells, where only one bead will fit in 
each well. Enzyme beads (containing sulfurylase and luciferase) are layered into 
the wells of the PicoTiterPlate.  The sequencing reaction is based on a sequencing-
by-synthesis method called pyrosequencing [239]. The sequencing reagents 
(containing buffers and nucleotides) are flowed across the wells of the plate. The 
nucleotides are added sequentially in a fixed order across the PicoTiterPlate 
during the sequencing run. During the nucleotide flow, millions of copies of DNA 
bound to each of the beads are sequenced in parallel. When a nucleotide 
complementary to the template strand is added into a well, the polymerase 
extends the existing DNA strand by adding nucleotide(s). Addition of one (or 
more) nucleotide(s) generates a light signal that is recorded by the CCD camera in 
the instrument. The signal strength is proportional to the number of nucleotides 
incorporated. Data are stored in standard flowgram format (SFF) files for 
downstream analyses. 
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Figure 10. Overview of the 454 sequencing system. 
 
 
2.6.3 UDPS data analyses  
The data produced from UDPS place substantial demands on data handling and 
quality control. The UDPS technology has higher error rate compared to Sanger 
sequencing, which means that it may be difficult to distinguish rare, but genuine, 
variants from artifacts generated in the cDNA synthesis, PCR or sequencing 
reaction. Homopolymeric stretches (of three or more of the same nucleotide) are 
particularly problematic due to difficulties in interpretation of the 
chemiluminiscent signal. Researchers are using different bioinformatic 
approaches to identify, remove or correct these sequencing artifacts, by in-house 
cleaning strategies [228, 240-242] or bioinformatic programs such as ShoRAH 
[243] and Segminator [244]. Which strategy to use is dependent on the specific 
data set and factor such as read-length and if assembly tools needs to be used.  
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3 MATERIALS AND METHODS 
 
3.1 PATIENT MATERIAL 
All patient samples used in the studies were retrieved from the HIV biobank at the 
Swedish Institute for Communicable Diseases. The biobank was established in 
1985 and contains more than 35,000 clinical samples (serum, plasma, PBMC 
and/or HIV isolates). The patient plasma samples used in Paper I, Paper II and 
Paper III, were collected between 1989 and 2003 and have been stored at -70°C 
or -20°C. Some samples had been freeze-thawed prior to our analyses. 
  
In Paper I, six HIV-1 subtype-B-infected individuals who experienced virological 
treatment failure were selected and a total of 40 plasma samples from these 
patients were analyzed. All patients, except one, had later undergone treatment 
interruption. The treatment histories of the patients differed, but all started 
therapy before the HAART era and all had received regimens that contained 3TC, 
AZT and d4T. Five of six patients were sampled before any treatment was 
initiated. All patients were sampled two to six times during treatment, i.e. the first 
available sample after treatment initiation and additional samples obtained 
during therapy failure. Finally, five patients were sampled following treatment 
interruption.  
 
In Paper II, four plasma samples used in Paper I were selected. Samples A, B, C 
and D in Paper II are the same as samples 6.4, 2.5, 4.5 and 3.5 from Paper I, 
respectively. The first number corresponds to the patient number and the second 
number corresponds to the sample in the series. Sample A and B were used to 
study repeatability, effects of sequencing direction and influence of primer related 
selective amplification. Plasma samples C and D were used to generate two 
molecular clones (clone 1 and clone 2) for studies on UDPS sensitivity and in vitro 
PCR recombination. These two clones were chosen on the basis of sequence 
dissimilarity with the aim to maximize the number of informative sites in the pol 
amplicon of interest.  
 
In Paper III, three HIV-1 subtype-B-infected patients with HIV-1 populations that 
switched coreceptor use to include CXCR4 during infection were selected and four 
to nine plasma samples from each patient were investigated. Information about 
coreceptor use was available in the database that is linked to the biobank and was 
based on MT-2 phenotypic tests performed on PBMC isolates at the time of 
sampling. For two patients, the first samples were obtained during early PHI. 
Thus, when the first study sample was obtained, patient 1 and patient 2 had a 
negative HIV-1 antibody test and positive HIV-1 antigen and RNA tests, which is 
consistent with a classification into Fiebig stage II. Patient 3 was classified into 
Fiebig stage IV-V based on a positive antibody test on ELISA and incomplete 
Western blot pattern (see section 2.4.2 on HIV-1 infection and pathogenesis). 
 
In Paper IV, patient material was not used, however sequences from control 
samples (clones) from Paper I were studied in more detail. The characteristics 
and reproducibility of sequencing errors was investigated in a SG3Δenv plasmid 
clone datasets that had been generated in three separate UDPS runs.  
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3.2 METHODOLOGIES 
3.2.1 UDPS library preparation 
The depth of UDPS analyses depends on the error frequency of the method (see 
section 3.2.2 below) and the number of input DNA templates. To obtain a high 
recovery of templates it is important to use sensitive and robust methods for RNA 
extraction, cDNA synthesis and PCR amplification. In Paper I, substantial efforts 
were invested in evaluating and comparing different approaches for RNA 
extraction, cDNA synthesis and PCR amplification, with the aim to maximize the 
number of plasma HIV-1 RNA molecules that were extracted, reverse transcribed, 
PCR amplified and finally subjected to UDPS. The final optimized protocol is 
presented below in Figure 11 and was used in all papers. Each sample was tagged 
with sample-specific sequence tags during the PCR to enable multiplexed UDPS 
sequencing. Before UDPS, the PCR amplicons were purified and the DNA 
concentration and purity was determined using Nanodrop, Qubit and Agilent 
2100 bioanalyzer. After these quality controls, the PCR amplicons were pooled 
and sequenced in both forward and reverse direction on the 454 Life Science 
platform according to the manufacturer’s instructions. The 454 GS FLX, with a 
read length of about 200 bp, was used in all papers. In addition, the 454 GS Junior 
System was used for some samples in Paper III. For detailed information about 
the specific procedure see materials and methods in Paper I and Paper III. 
 
 
 
 
 
Figure 11. Schematic illustration over the experimental setup used in all papers. 
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In Paper I, Paper II and Paper IV a fragment of 167nucleotides in the pol gene 
(positions 3058 to 3226 in HxB2, GenBank accession number K03455) 
corresponding to amino acids 171 to 224 in RT was amplified (Figure 12). In 
Paper III, a fragment covering the V3 region in the env gene (positions 7010 to 
7332 in HxB2, GenBank accession number K03455) was amplified.  
 
 
 
Figure 12. HIV-1 pol amplicon. The NRTI and NNRTI drug resistance mutations are shown in blue 
and red, respectively. The drug resistance positions studied in Paper I are the NRTI mutations 
M184V/I, L210W, T215Y/F, K219Q/E and the NNRTI mutations Y181C/I/V, Y188C/L/H, G190S/A. 
(Kindly provided by Johanna Brodin). 
 
3.2.2 Data filtering 
Bioinformatic software was written in PERL to manage, clean and analyze the 
UDPS data. The data cleaning method removed reads with characteristics 
associated with UDPS sequencing errors. Unlike some other methods we did not 
attempt to correct errors since we did not want to risk creating sequence variants 
that did not exist in the original patient sample. A similar data handling and 
filtering strategy was used in all papers and is summarized below. 
 
1. Each sample was identified by their sample-specific sequence tags.  
2. Reads with <80% similarity (Paper I, II and IV) or <70% similarity 
(Paper III) to the corresponding Sanger sequence were filtered. 
3. Reads containing ambiguous bases (Ns) were filtered.  
4. Reads that did not cover the entire region of interest (amino acids 
180–220 in RT, position 3087 to 3206 in HxB2, GenBank accession 
number K03455) (Paper I, II and IV) were filtered.  
5. Remaining reads were imported into the GS amplicon software (Roche, 
Penzberg, Germany) and aligned.  
6. The data were compressed by PERL scripts that identified unique 
sequence variants in forward and reverse direction (Paper I, II and IV) 
and counted the number of reads per variant. In Paper III, forward 
and reverse reads were combined, due to low number of reads in the 
reverse direction compared to the forward direction. The tally for each 
variant was retained as part of the sequence name for further analyses.  
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7. The alignment was extracted and cut to the region of interest amino 
acid 180–220  in pol (Paper I, and II) or position 7137 to 7242 in the 
V3 region (Paper III). In Paper IV, the entire length of the pol reads 
were retained.  
8. Since UDPS errors are known to be concentrated to homopolymeric 
regions, reads with out-of frame insertions or deletions were removed, 
while reads with in-frame indels (i.e. ±3, 6, 9 nucleotides) were 
retained.  
9. Finally, the alignments were manually inspected and any remaining 
variants with frameshifts or stop codons were removed.  
10. For Paper I, II and IV, the unique variants found in forward and 
reverse direction were compared and the abundance of the variant 
was set to the sum of the forward and reverse tallies. However, if 
frequencies of the forward and reverse reads differed by more than a 
factor of 10 we made the assumption that a systematic error had 
occurred during UDPS and adjusted the frequency of the variant to the 
lower of the two estimates. Finally, variants were discarded from 
further analyses if the variant was absent in either forward or reverse 
direction. For Paper IV, no more filtering was done beyond this step.   
11. In Paper I and Paper II, both drug resistance analysis and individual 
variant analysis were done on the datasets using two different cut-off 
approaches:  
 Paper I - Drug resistance analyses: individual average cut-off 
values (with a 95% confidence interval) were calculated for 
each drug resistance mutation positions using data from the 
SG3Δenv plasmid sequenced on three occasions. These cut-off 
values, which were adjusted to each sample (since different 
number of reads were obtained for each sample), were used to 
evaluate if the frequency of drug resistance were significantly 
higher than the background error rate at that position (Chi-
square test with correction for continuity). 
 Paper I and Paper II - Individual variant analyses: variants 
were classified as high-confidence variants or as probable 
sequencing artifact by using the overall average error rate 
generated from the three SG3Δenv plasmid datasets as cut-off. 
Variants with prevalence significantly higher than the cut-off 
value was retained and variants below the cut-off were 
discarded.   
12. In Paper III, the number of reads from each sample was adjusted to 
the template molecule availability. Since the number of templates 
varied between samples due to differences in viral load, high-
confidence variants could not be calculated based on cut-off values. 
Instead variants represented by one read were removed to reduce the 
dataset before phylogenetic analyses.  
 
3.2.3 Diversity calculations 
In Paper I and Paper III, the pair-wise distances for each sample were calculated 
using MEGA 4 with the Tamura-Nei model with gamma distributed rates across 
sites (α=0.5). The average genetic distance per sample was calculated using an in-
house PERL script that weighted sequence variants according to their abundance. 
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3.2.4 Coreceptor use and phylogenetic analyses 
In Paper III, phenotypic coreceptor testing had been determined by the MT-2 
assay at the time of sampling. The coreceptor use of each individual V3 sequence 
was predicted using the bioinformatic algorithms PSSMx4/r5 and 
geno2pheno[coreceptor]. Variants were predicted to use CXCR4 if the PSSM score was 
above -2.88 and the geno2pheno FPR was below 5.75%, according to European 
guidelines [151]. Variants that fulfilled only one of these criteria were considered 
to have an uncertain coreceptor use, whereas variants that did not fulfill any of the 
two criteria were considered to use CCR5. The evolutionary relationships were 
analyzed by maximum likelihood trees constructed using PhyML 3.0 and the best-
fit-model of nucleotide substitution identified by jModelTest.   
 
3.2.5 Ethical considerations 
For Paper I, Paper II and Paper III, ethics application was approved by Regional 
Ethical Review board in Stockholm, Sweden (Dnr 52/2008-77). In Paper IV, no 
patient material was used and therefore no ethics application was needed. 
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4 RESULTS AND DISCUSSION 
 
In this thesis, I have used UDPS to dissect the HIV-1 quasispecies, with the aim of 
studying HIV-1 evolution during drug resistance development and coreceptor 
switch, Paper I and Paper III, respectively. To enable deep sequencing with the 
UDPS methodology, we careful optimized all protocols upstream from UDPS 
(Paper I) and  developed bioinformatic tools to clean and handle the data (Paper 
I and Paper IV). In Paper II, we evaluated the performance of our UDPS 
methodology.  Finally, preliminary results from an ongoing project, with the aim 
to further reduce the error frequency by introducing molecule-specific tag 
sequences (primer IDs), will be presented and discussed. The results will be 
presented in three main sections. 1) Performance of UDPS. 2) Dynamics of HIV-1 
quasispecies. 3) Methods to reduce UDPS error frequency. 
 
 
4.1 PERFORMANCE OF UDPS  
4.1.1 Experimental setup 
The UDPS technology has been used extensively during the last few years. For 
example to study cancer-associated genes in humans [245, 246] and minority 
variants within the HIV-1 quasispecies, including drug resistance (Paper I; [207, 
238, 247-249], coreceptor use (Paper III; [240, 241, 244], APOBEC3 
hypermutations [250] and coevolution in the nef gene [251]. Recently, whole 
genome deep-sequencing of HIV-1 has been described [252] as well as 
improvements in the UDPS accuracy by molecule-specific tags [253, 254]. The 
depth of UDPS depends on the number of viral templates that can be successfully 
extracted and amplified from the patient sample [207, 255], the error rate of PCR 
and UDPS, and the efficiency of cleaning the UDPS data from such errors. Different 
bioinformatic approaches has been developed to identify, remove or correct these 
sequencing artifacts, by in-house cleaning strategies (Paper I; Paper IV;[240-
242]) or bioinformatic programs such as ShoRAH [243] and Segminator [244]. 
The approaches have been reported to decrease the average error rate to levels 
ranging from 0.05% (Paper I; [242]) to 0.43% [256] errors per nucleotide. 
Frequency estimates has been shown to be reproducible for variants constituting 
≥1% [241] and >0.27% (Paper II) of the population. 
 
We have developed optimized pre-UDPS protocols (i.e. RNA extraction, cDNA and 
PCR) and we have quantified the number of HIV-1 cDNA templates subjected to 
UDPS, which ranged from 2,300 to 570,000 (Paper I) and 56 to 93,632 in Paper 
III. Such quantification verified that the number of templates was sufficient for 
deep sequencing. It should be noted that quantification of viral templates before 
UDPS has not always been used in other UDPS studies. If too few templates are 
recovered the depth of the UDPS analysis would be too low and a single genome 
sequencing approach [257] might be more useful. Furthermore, the quantification 
was done by a PCR system with the same sensitivity as the PCR used in the library 
preparation. Occasionally, we observed low efficiency of preparation, which might 
be explained by the fact that some samples had been suboptimal stored at -20°C 
for long time or repeated freeze-thawed. In Paper I and Paper III, 3,837 to 
41,940 and 279 to 32,094 reads per sample were generated, based on template 
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molecule availability. Some samples were over-sampled, which means that the 
number of templates were lower than the number of reads. Over-sampling can 
theoretically remove some of the stochasticity in the distribution of variants. 
However, in cases of over-sampling it is important to remember that each read 
does not corresponds to an individual virus particle, which means that the 
sequence depth is affected. The maximal sequence depth of the samples with the 
lowest number of templates was 0.04% (1/2300) in Paper I and 1.8% (1/56) in 
Paper III. By analyzing the frequency and distribution of sequencing errors in 
experiments on plasmid clones we were able to develop bioinformatic scripts that 
were used to clean the data (Paper I and Paper IV) from sequencing artifacts and 
to determine statistical cut-off values for detection of high-confidence minority 
resistance mutations and genetic variants. The error rate across sites was 
estimated to be approximately 0.05% errors per nucleotide after data cleaning for 
both the pol amplicon (Paper I and Paper IV) and the V3 amplicon (Paper III) as 
well as for the 454 GS FLX and 454 GS FLX Junior Titanium platforms.  
 
As expected, the error rate was not uniform across sites. For this reason we 
estimated the UDPS error rate for each drug resistance position (Paper I). These 
cut-off values were adjusted according to the number of reads generated for each 
sample. The average cut-off value for drug resistance mutations was estimated to 
be 0.05% (range 0.014 - 0.29%) and the average cut-off for high-confidence 
variants was estimated to be 0.11% (range 0.09 - 0.21%).  We later observed 
(Paper IV) that the site-specific error rates in cleaned data were moderately, but 
still significantly, correlated between runs. There was also a moderate correlation 
between errors in forward and reverse reads of the same sample and run. 
Moreover, there were significantly more transition errors compared to 
transversion error after the data had been cleaned. Collectively the results from 
Paper IV indicate a many of the errors that remain after data cleaning were 
introduced during the PCR that preceded pyrosequencing. This means that it 
might be more correct to use individual cut-offs for transitions and transversions 
than the site-specific cutoffs that we used in Paper I. 
 
In Paper I, Paper II, Paper III and Paper IV an average of 30%, 20%, 15% and 
31% of the total number of reads were filtered during the data cleaning process, 
respectively. The lower percentage of reads removed in Paper II and Paper III is 
due to that no cut-off values were used. The average error frequency on raw reads 
was estimated to be 0.54% per nucleotide and the filtering strategy reduced the 
error rate approximately 10-fold. Thus, the filtering of 1/6 to 1/3 of the reads 
greatly improved the signal to noise ratio. The removal of reads with indels, which 
was mainly introduced during UDPS, had the greatest impact on reducing the 
error frequency. The sources of errors and the data filtering approach are 
discussed in more detail in section 4.3.1.  
 
Taken together, after data cleaning the sensitivity of our UDPS methodology was 
primarily limited by errors introduced during PCR or the low number of templates 
for some samples. 
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4.1.2 UDPS evaluation 
In Paper II the performance of UDPS was evaluated for experimental noise and 
data variability, such as repeatability, effects of sequence direction, sensitivity, 
influence of primer-related selective amplification and in vitro PCR recombination. 
 
To evaluate the repeatability of frequency estimates of HIV-1 variants, we 
performed repeated UDPS analyses of two patient plasma samples (Paper II). 
We found that a repeated measurement had a 95% likelihood of lying within 
±0.5log10 of the initial estimate. Thus, a variant that was found in 100 reads in 
the first measurement had a 95% likelihood to lie between 32 and 316 reads in 
the second measurement. Interestingly, the repeatability was similar for rare 
and more abundant variants. We compared our results with those of Poon et al. 
[251], who used variance-to-mean ratios to investigate repeatability. The 
average variance-to-mean ratio in our experiments was 3.2 × 10-4, which is more 
than 20 times lower than that estimated by Poon et al. [251]. In addition, Poon et 
al reported that some variants representing 1 - 5% of the virus population in one 
analysis were not detected when the analysis was repeated. Similarly, Gianella et 
al. recently reported a low level of repeatability in detection and quantification 
of minority drug resistance mutations [258]. With our UDPS methodology, we 
repeatedly identified variants that represented >0.27% of the virus population. 
Thus, variants within the HIV-1 quasispecies that are as rare as 1 in 370 could be 
repeatedly detected. The reason for the differences in repeatability between 
these studies and our, is not clear, but could be due to differences in both 
laboratory methodology, sequencing approach and data cleaning. For instance 
Gianella et al. used a shotgun sequencing approach, which generally gives lower 
and less predictable sequence depth (coverage) than amplicon sequencing. One 
can also speculate that even lower frequencies could have been obtained if the 
samples would have been over-sampled, which was not the case in our study 
(Paper II). 
 
In Paper II, we evaluated the effect of sequence direction on variant abundance 
estimates, which can be of importance in e.g. data cleaning. Bidirectional UDPS has 
been described in only a few studies (Paper I; [246, 256]), where variants were 
considered ‘‘true’’ if they were present in both sequence directions. We found that 
the difference in variant abundance between forward and reverse sequence 
direction in general was relatively small and approximately as great as the 
difference between UDPS runs (repeatability experiment described above). 
However, in contrast to the repeatability experiments, the agreement between 
forward and reverse analyses was higher for common variants than for rare 
variants, which was not surprising due to stochasticity in the ability to detect rare 
variants with abundance close to the detection limit. In fact, it was somewhat 
unexpected not to see this correlation in the repeatability experiment described 
above. In addition, some variants only exceeded our cut-offs for high-confidence 
variants in one sequence direction. 
 
The sensitivity of our UDPS methodology to identify minority variants 
representing 0.5 and 0.05% of the population was evaluated in Paper II by using 
mixed known concentrations of two molecular clones. The minor variant was 
identified in both experiments, but their proportions were somewhat higher than 
expected, i.e. 2.2% and 0.31% respectively. This may be a stochastic effect, but we 
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cannot exclude the possibility that minority strains may have been systematically 
overestimated for instance if the major variants reached the PCR plateau earlier 
than rare variants. Artificial HIV-1 mixtures of 1% and 0.1% have previously been 
analyzed by Tsibris et al. [241] and Zagodi et al. [242], respectively. Our results 
are in agreement with these studies and suggest that it is possible to detect and 
quantify minor variants of the HIV-1 population, at least when the minor variant is 
clearly genetically distinguishable from the major variants such as is expected in 
the case of superinfection. If the variants are very similar (for instance a single 
transition) it is more challenging to differentiate between true variants and 
variants that have arisen due experimental error. 
 
Moreover, in Paper II, the potential influence of primer-related selective 
amplification on estimation of variant abundance were evaluated using two 
nested primer sets with unique primer binding sites that targeted the same region 
in the pol gene. These primers targeted highly conserved, but separate, primer 
binding sites and included wobbled bases to further reduce the likelihood of 
nucleotide mismatches to the targets. Despite these efforts the estimations of 
variant abundance differed between the two primer sets. We were able to detect 
variants down to 0.2% of the viral population with both primer sets. However, one 
variant, which was estimated to represent 46% using the original primers, was 
detected in only 5.6% of the reads obtained with the alternative primers. As a 
result the limits of agreement was approximately two times wider than when the 
sample was re-analyzed with the original primer set. This suggests differential 
amplification of certain HIV-1 variants, presumably due to primer-related 
selective amplification. Thus, optimal primer design may be very important when 
UDPS is used to analyze the population structure in divergent target sequences, 
like HIV-1 populations. One could even speculate if multiple primer sets should be 
used in order to fully and correctly characterize HIV-1 variation. 
 
UDPS has been used to study genetic variants and mutational linkage, but such 
analyses are only valid if the frequency of in vitro recombination is zero or close to 
zero. The most obvious source for recombination is the PCR, which is known be 
associated with incomplete extensions and template switching, which results in 
vitro recombination. The frequency of PCR recombination varies considerably 
with amplicon length and amplification condition [259-263]. To determine the in 
vitro recombination frequency in our experimental system we mixed two 
molecular clones in a 50:50 ratio before PCR amplification and UDPS. The two 
clones were selected so that they differed by 13 informative sites that were 
distributed across the amplicon. In addition, to study if the frequency of in vitro 
PCR recombination may be influenced by the number of target molecules we 
tested both 100,000 and 10,000 HIV-1 DNA templates as input in the outer PCR. 
The same dataset was used in Paper I and Paper II, but the analysis was extended 
in Paper II. Recombinant sequences were defined as sequences with replacement 
of at least two signature nucleotides that were adjacent (Paper I) or irrespective 
of whether they were adjacent or not (Paper II). The later definition is more 
conservative than the first and thus the estimated recombination frequencies 
were a little higher in Paper II compared with Paper I. In Paper I the estimated 
recombination frequency was 0.76% and 0.27% compared with 0.89% and 0.29% 
in Paper II, in the 100,000 and 10,000 template experiments, respectively. 
Importantly, the individual frequency of most of the recombination variants was 
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below the cut-off for high-confidence variants. Thus, these variants would not be 
considered as genuine in data analysis. 
 
In summary, our results show that the repeatability of frequency estimates of 
HIV-1 variants was good for major as well as minor variants in patient plasma 
samples. This indicates that the experimental noise introduced during RNA 
extraction, cDNA synthesis, PCR and UDPS was low. However, for rare variants in 
vitro recombination and effects of sequence direction needs to be considered. 
Finally, the design of primers for PCR amplification is important during UDPS as 
well as for all PCR-based methods, since primer-related selective amplification 
can skew frequency estimates of genetic variants.  
 
 
4.2 DYNAMICS OF HIV-1 QUASISPECIES 
4.2.1 Minority variants  
Minority HIV-1 variants have in recent reports shown to be of clinical significance, 
this applies especially to mutations associated with NNRTI resistance [206-212] 
and minority variants harbouring X4/R5X4 phenotype [217]. Such minority 
variants could either be transmitted or could have evolved over time within the 
patient. Theoretically, mutations associated with drug resistance are expected to 
occur naturally at low levels within the HIV-1 quasispecies, even if a patient has 
never received treatment [205]. By simple calculations, using the RT error rate of 
1.4x10-5 mutations per site and generation [44] and viral production rate of 1010 
virions per day [51] it can be estimated that all nucleotides in the HIV-1 genome 
mutate on average around 105 times per day in an HIV-1 infected individual. In 
Paper I and Paper III, we investigated the pre-existence of drug resistance in 
treatment naïve patients who later experienced treatment failure and pre-
existence of X4-virus in patients whose virus later switches to CXCR4 use, 
respectively.  
 
In Paper I, we found significant levels of the resistance mutations M184I (4 of 5 
patients), T215I and/or T215A (4 of 5 patients) ranging from 0.02%–0.12% in 
plasma samples obtained before treatment was initiated. In contrast, we did not 
find any significant pre-existence of the drug resistance mutations M184V, Y181C, 
Y188C, L210 or T215Y/F. The presence of M184I, T215I and T215A in treatment 
naive patients was somewhat expected since these drug resistance mutations only 
differ by one transition from wild-type (see discussion of Paper IV). For the same 
reason we would have expected to find M184V, Y181C and Y188C which also are 
transitions, but not T215Y/F since the latter are double mutants (containing 
transversions) compared to wild-type. One explanation for the absence of 
significant levels of M184V, Y181C and Y188C could be due to the higher cut-off 
values for high-confidence mutations at these positions (e.g. 0.15% for M184V 
compared to 0.07% for M184I). Since both the isoleucine (ATA) and valine (GTG) 
are due to transitions from the wild-type methonine (ATG), the higher cut-off seen 
in the M184V position is not explained by the transition vs. transversion error bias 
that we observed in Paper IV, but rather indicates presence of context-dependent 
errors (Paper IV). The T215I and T215A mutations involve two transversions 
compared to wild-type, thus their presence was somewhat unexpected. It should 
also be acknowledged that we cannot exclude that these patients were infected 
with resistant viruses which later reverted to the two T215 reversion mutations 
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T215I and T215A. The clinical relevance of the pre-existing drug resistance 
mutations found in our study is probably low. It has been shown that pre-existing 
M184I does not necessarily lead to virologic failure [212]. The same results have 
been shown for M184V mutation, which has been studied more extensively [206]. 
T215I and T215A do not by them self confer phenotypic resistance [186]. 
 
G->A mutations are the most common type of errors introduced by RT [44, 264], 
which appears to be the reason why M184I most often precedes the emergence of 
M184V during 3TC resistance in vivo (Paper I, [264]). This could explain why we 
found significant levels of pre-existing M184I in 4/5 patients (Paper I). In a 
previous study, the natural occurrence of M184V, Y181C, T215Y and T215F was 
estimated in samples obtained before the era of ARV to be 0.5%, 1.0%, 1.0% and 
0.7%, respectively [265]. In Paper I we did not detect any preexistence of these 
mutations even though our method allowed detection of resistance mutations 
below the frequencies presented by Johnson et al. However, since we only studied 
five patients our study does not have power to draw conclusions about these 
differences.  
 
In Paper III, we investigated if X4-viruses were present as a minority populations 
during PHI in three patients with HIV-1 populations that later switched 
coreceptor use to include CXCR4. UDPS analysis showed that the X4 variants that 
emerged in these three patients after coreceptor switch were not present during 
PHI and that the X4 variants most probably evolved from the R5 population 
during the course of infection rather than being transmitted as minor variants. 
However, we cannot exclude that X4 virus was transmitted and suppressed to 
levels below the detection limit of UDPS during the first weeks of infection. Thus, 
X4 virus could have been latent e.g. in the lymph nodes until the coreceptor 
switch. Nevertheless, if this was the case in these three patients we would 
probably have seen a greater genetic difference between the R5 and X4 variants 
that coexisted in the switch samples.   
    
4.2.2 Virologic failure due to drug resistance 
In Paper I, we investigated the development of drug resistance in six patients 
during treatment failure due to suboptimal treatment. Our UDPS analyses showed 
that different wild-type variants co-existed within each patient before initiation of 
therapy. Following start of therapy, virus variants with several different 
combinations of resistance mutations evolved and co-existed. However, during 
prolonged treatment failure the number of viral variants decreased, suggesting 
genetic bottle-necking due to a selective advantage of certain variants. This was 
accompanied by a gradual increase in the prevalence of variants with specific 
linked drug resistance mutations (in particular variants with M184V+T215Y and 
M184V+L210W+T215Y) and wild-type variants were only detected in one patient 
during therapy failure. However, wild-type variants might have been present 
below our detection limit of 0.11%, because it is well known that there is residual 
low level viremia (approximately 1 plasma HIV-1 RNA copy/ml) during long-term 
successful HAART. These viral variants often are drug-sensitive [161, 266] 
because they are released from stable reservoirs that were established before 
therapy was initiated [267]. It is reasonable to assume that such drug-sensitive 
variants are released also during non-suppressive HAART, but at such a low level 
that they were not detected in our UDPS analyses. In contrast to our results, Allers 
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et al. reported significant levels (0.6 to 30%) of lamivudine sensitive variants in 
viral population from patients failing 3TC-containing therapy [268]. However, 
these patients received dual-therapy with 3TC and AZT, while our patients 
generally received three or more drugs. 
 
4.2.3 Treatment interruption and drug resistance  
Since many primary drug resistance mutations reduce fitness [269], drug-
sensitive viruses rapidly reemerge after complete treatment interruption [229, 
270]. However, the kinetics and detailed dynamics of this process is incompletely 
understood. In Paper I we showed that drug resistant variants decreased to 
undetectable levels a few months after complete treatment interruption even 
when highly sensitive UDPS was used. This indicates that these variants had quite 
low fitness in absence of therapy. The complete out-growth of drug-sensitive 
variants within a few months differs markedly from the findings in patients with 
transmitted drug resistance, where drug resistance may persist for many years 
[226, 271, 272]. Our findings might be of clinical relevance since we show that 
drug resistant variants may be very difficult to detect in patients with previous 
treatment failure even with highly sensitive UDPS technology. In contrast to our 
results, Le et al. found low abundance mutations associated with AZT/d4T 
resistance 2 to 7 years after treatment with these drugs had been stopped [247]. 
However, in contrast to our patients, the patients enrolled in their study continued 
therapy with other antiviral drugs. Additional studies are needed to investigate 
the dynamics of drug resistant minority variants after treatment interruption. 
Since drug resistant variants can become deposited in long term reservoirs [271, 
273] it would be interesting to analyze different cell compartments in addition to 
plasma. 
 
4.2.4 Coreceptor switch 
X4 or X4R5 viruses emerge in about 70% of infected individuals in the later stages 
of infection [77, 110-112] by stepwise mutational pathway from R5 variants [274, 
275]. In Paper III, the coreceptor switch was studied in three patients. Our results 
show that the coreceptor switch was relatively abrupt rather than gradual since 
the preceding samples obtained 15-20 months prior to the switch contained only 
R5 virus. Phylogenetic analyses showed that distinct R5 and X4 clusters were 
present after the switch in all patients. In two of the patients X4 variants appeared 
to have emerged from the contemporary R5 population generating two or more 
statistically supported X4 clusters, which also supports the notion that the R5 to 
X4 switch is relatively quick as indicated by Bunnik et al.[274]. 
  
4.2.5 Primary HIV infection 
Several recent studies have indicated that most HIV-1 infections are established 
by one or a small number of infectious particles [70, 72, 73], resulting in low 
genetic diversity during PHI and a gradually increase during the asymptomatic 
course of infection [75, 78, 276, 277]. However, it is difficult to distinguish if the 
infection actually is established by several founder viruses, but only one or a few 
are selected due to replicative capacity, ability to bind to and infect host cells, 
number of virons produced or recognition by the immune system. Similar to the 
studies above, we observed one to three major variants during PHI of three 
patients (Paper III). The viral diversity during PHI in our study was 1.1 - 3.2%, 
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which is within the upper range of what has been reported before where the 
median viral diversity was 0.39% (range 0.04% - 3.23%) [276]. However, it is 
difficult to make exact comparisons between genetic diversities reported in 
these studies since different sequence methodologies have been used and the 
exact timing of sampling was different. Deep sequencing will naturally have the 
possibility to give a higher average genetic distance due to the higher coverage 
of variants compared with methods based on conventional Sanger sequencing 
techniques such as single genome sequencing.   
 
 
4.3 METHODS TO REDUCE UDPS ERROR FREQUENCY 
4.3.1 UDPS errors and data cleaning approach 
In Paper IV, we investigated the frequency and type of errors that occur during 
UDPS of a molecular clone corresponding to the same fragment of the HIV-1 pol 
gene analyzed in Paper I and Paper II. Based on these results we developed a 
strategy to clean UDPS data from sequencing errors. The cleaning strategy 
reduced the average error frequency per base from 0.54% to 0.055%, i.e. by a 
factor of 9.8. UDPS errors are known to be over-represented in homopolymeric 
regions [246, 256, 278], but this bias was removed by our data cleaning strategy. 
However, the UDPS errors that remained after data cleaning were 59-times more 
likely to be transitions than transversions, which indicates that a substantial 
proportion of the errors were introduced during PCR. This conclusion was 
corroborated by the finding of moderate, but still highly significant, correlation of 
sequencing errors observed in forward and reverse sequencing direction of the 
same amplicon. If the errors were introduced during UDPS, the probability to 
detect the same error in both forward and reverse direction would have been 
lower. The transition vs. transversion bias needs to be considered when cut-offs 
for detection of minority mutations are determined. Thus, it would have been 
more correct to base the cut-offs used in Paper I on transitions and transversions 
instead. 
 
In agreement with previous reports, we found that errors in raw UDPS data were 
over-represented in homopolymeric regions (Paper IV). Indels, especially 
deletions, was the most frequent error type [279], but substitution errors also 
occurred. Indels are mainly created in silico during the interpretation of the 
intensity of chemiluminescent signal in homopolymeric regions [280]. In 
contrast, substitution errors may be introduced both in the PCR and in the UDPS 
[242, 246]. Our cleaning strategy did not manipulate the sequences and thereby 
did not create artificial new variants. However, it cannot be excluded that the 
cleaning strategy may occasionally have filtered genuine sequence variants 
when it was applied on UDPS data from patient samples. We observed that the 
error frequencies per nucleotide were unevenly distributed across the sequence 
fragment. To understand in which steps of the sequencing procedure the errors 
had been introduced, we investigated the characteristics of the substitution 
errors that remained after data cleaning. We found that the site-specific error 
frequencies in forward and reverse sequencing direction of each of the three 
runs were significantly correlated, which indicates that a proportion of the 
errors were introduced in the PCR. As presented in the results section (Paper 
IV), such correlation is only expected for errors that are introduced in early PCR 
cycles, which means that the proportion of PCR errors that remained after data 
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cleaning may have been higher than indicated by the correlation coefficients, 
which were relatively low. There was also a significant correlation of site-
specific error frequencies between runs, which indicates presence of context-
dependent errors that may have occurred in the PCR and/or UDPS. 
  
4.3.2 Reducing errors by molecule-specific tags  
In Paper IV we describe that the depth of UDPS is limited by errors introduced 
during PCR and/or UDPS. Here, preliminary results from “The molecule-specific 
tag project” are described. In this project we have attempted to improve the UDPS 
methodology to allow more accurate detection of minority viral variants. We have 
used this method to amplify the same fragment of 167 nucleotides in the pol gene 
as in Paper I, Paper II and Paper IV, however the method is generic and other 
genes/organisms can be targeted. The method is based on the following key 
features: a reverse primer with a unique sequence tag of 10 degenerated 
nucleotides (410 = 1,048,576 unique combinations) is added in the cDNA 
synthesis, giving each individual template a specific genetic barcode (tag). Next, a 
one cycle PCR generates double stranded DNA using platinum taq high fidelity 
enzyme.  The uracil containing reverse primer is degraded by uracil-DNA 
glycosylase and NaOH. The double stranded DNA template is amplified with a 
semi-nested PCR and subsequently pooled before UDPS. The generated UDPS 
reads are sorted based on their sample and molecule tags. At least three reads is 
needed from each template to create a consensus sequence, which results in 
almost complete elimination of experimental errors that have occurred after 
cDNA synthesis, i.e. during PCR and UDPS. After we had initiated our project other 
groups have published methods that apply the same basic principle, i.e. tagging of 
template molecules to allow them to be re-sequenced [253, 254]. Jabara et al 
referred to the template-specific genetic barcodes as primer IDs.  
 
 
Figure 13. Experimental setup. Rev, reverse primer. m, molecule-specific tag (primer ID). B, B 
adaptor. UDG, Uracil-DNA glycosylase. Fw, forward primer. A, A adaptor. s, sample-specific tag. 
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Five patients with documented TDR (based on Sanger sequencing) and one 
plasmid clone sample were selected for sequence analysis using the primer ID 
approach. A total of 408,717 UDPS reads, of which 41,387 reads originated from 
the plasmid clone were generated. The average error frequency per nucleotide 
for the plasmid sequences without consideration of primer IDs was estimated to 
be 0.6% (which is similar to the raw error rate in previous UDPS runs, Paper 
IV). The reads originating from each primer ID were aligned and a consensus 
sequence was generated for each template. A total number of 162 consensus 
sequences were generated for the clone. An example of an alignment from five 
reads with the same primer ID is shown in Figure 14. The alignment contains 
both substitution errors and deletions but since these errors are in minority 
(<50% of the nucleotides each position) they are not present in the consensus 
sequence, which represents the “error-free” sequence of the template molecule. 
After creating a consensus sequence for each unique primer ID sequences the 
error frequency was reduced five-fold to 0.13%, without any prior cleaning of 
the reads.   
 
 
 
 
Figure 14. An alignment of reads originating from the same template with a unique molecule-
specific tag sequence. The variation seen in the alignment are due to errors introduced during 
PCR or sequencing. The generated consensus sequence contains no errors.   
 
There are several reasons why the error frequency of the method was not 0%. 
As previously shown, deletions were the most common error, followed by 
insertions and substitutions (Paper IV). Most of the deletions and insertions 
were localized in homopolymeric regions. For a small number of template 
molecules >50% of the reads had an identical error in a homopolymeric region 
(usually a deletion), which generated an incorrect consensus sequence of this 
template molecule. By correcting these indels in homopolymeric regions the 
error frequency was reduced to 0.06% errors per nucleotide.  
 
Eight unique consensus sequences still contained errors relative to the plasmid 
sequence. These errors were substitution errors (n=4) or insertions (n=3) in 
non-homoplymeric regions that could have three sources: 1) The same type of 
systematic UDPS error as described above; 2) A PCR error in the first PCR cycle; 
or 3) Polymorphisms in the plasmid templates. We observed a high substitution 
rate at one position where over 10% of the reads harbored a T->C transition 
(Figure 15, lower graph). When studying the individual alignments the mutation 
was present in all reads originated from nine template molecules and was 
uncommonly found in other templates. Thus, it is unlikely that this mutation 
originated from PCR or UDPS errors due to the low probability of generating the 
same substitution error at the same site at nine separate templates. In addition, 
we have not observed similar result in any previous studies using this pol 
fragment (Paper I, Paper II and Paper IV). Hence, a more likely explanation for 
this error was a polymorphism in plasmid. When these sequences were removed 
the error frequency was reduced to 0.0006% errors per nucleotide.  
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Figure 15. Error frequency per nucleotide. The upper graph shows the error rate per site for the UDPS 
methodology used in Paper I, Paper II, Paper IV, after data cleaning. The lower graph shows the error 
rate per site using molecule specific tags after consensus formation. The bars are color-coded 
according to the substitution error. Homopolymeric regions are shaded. 
 
It needs to be emphasized that the 7 unique consensus sequences containing 
errors were still present and that they constituted 4% of the consensus variants 
(7/162), shown in Figure 16. This was higher than expected to be generated 
from first two single PCR cycles, which theoretically would generate an error in 
0.14% of templates (4.33x10-6erros/bp x 167bp x 2 PCR cycles). In addition, the 
fact that 3/5 of the substitution errors were transversions, which are uncommon 
as PCR errors (Paper IV), further indicates that the origin of these errors are 
more complex and require further investigation.  
 
We are currently analyzing the UDPS reads from the patient samples, generating 
consensus sequences for each template, to accurately quantify minor TDRs, such 
as M184V. Our preliminary results show that this method has the potential to 
increase the depth of UDPS by reduced error frequency per nucleotide from 
0.6% down to 0.0006%. Furthermore, the method gives an exact count of the 
number of analyzed templates which eliminates the need for independent 
template quantification as well as problems with unintentional re-sampling of 
the same templates. However, we and Jabara et al. have observed an unbalance 
in the number of reads per template [253], which might be due to that some 
primer IDs are more favorable for amplification than others. Moreover, in our 
data we observed PCR errors in primer IDs, which can lead to false templates. 
However, by grouping the primer IDs based on similarity, thus merging primer 
IDs that only differ by one or two nucleotides from a common primer ID, the risk 
of generating false templates can be reduced. In addition, we have observed 
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lower number of primer IDs than expected in the clone data. From the 10,000 
plasmid templates subjected to the experiment, only 162 unique templates were 
detected. This was due to three main reasons: 1) A lower recovery of templates 
throughout the experimental setup than expected. 2) Skewness of amplification 
of individual primer IDs due to secondary structure or other factors making 
some primer IDs more favorable for amplification. 3) A lower total number of 
reads generated from the 454 GS FLX titanium run than expected. Thus, several 
primer IDs were found in fewer than three reads and were discarded since no 
consensus could be constructed.  
 
 
 
Figure 16. Alignment of the 12 unique consensus sequences representing individual plasmid 
template. The first consensus sequence shows the correct plasmid sequence in which was 
observed in 80 consensus sequences. The number of reads is shown in brackets. Consensus 
sequence 1, 3 and 4 harbored the T->C constituting more than 10% of the reads.  
 
 
Taken together, we and others [253, 254] have shown that the addition of 
primer IDs to tag each template is a possible solution to remove artificial errors 
introduced during PCR, which is a step needed for all UDPS method used today. 
This method has the potential to increase the sequence depth and allow more 
accurate studies of the HIV-1 quasispecies. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
HIV-1 has the ability to quickly diversify and adapt to changes in its’ 
environment, such as evading the immune response of the host [12], altering cell 
tropism, and developing resistance to antiretroviral drugs [13]. In this thesis the 
UDPS technology has been used to dissect the HIV-1 quasispecies of HIV-1 
infected patients to study development of drug resistance and evolution of cell 
tropism. The UDPS methodology has been carefully optimized to maximize the 
depth and accuracy of our analyses. 
We and others have used the UDPS technology to study minority variants within 
the HIV-1 quasispecies, in regards to drug resistance (Paper I; [207, 238, 247-
249], coreceptor use (Paper III; [240, 241, 244], APOBEC3 hypermutations 
[250] and coevolution in the nef gene [251]. The depth of UDPS depends on the 
number of viral templates that can be successfully extracted and amplified from 
a plasma sample [207, 255], the error rate of PCR and UDPS, and the efficiency of 
cleaning the UDPS data from such errors. Thus, an experimental design that 
allows high recovery of HIV-1 templates together with an effective data cleaning 
strategy is important for successful UDPS analyses (Paper I, Paper IV). Different 
bioinformatic cleaning approaches have been reported to decrease the average 
error rate to levels ranging from 0.05% (Paper I, Paper IV; [242] to 0.43% 
[256] errors per nucleotide. Variant abundance estimates has been shown to be 
reproducible for variants constituting ≥1% [241] and >0.27% (Paper II) of the 
population. 
In Paper II, we have performed a series of experiments to evaluate the 
performance of our UDPS analysis. The results showed that the repeatability was 
good for major as well as minor variants in patient plasma samples, which 
indicates that the experimental noise introduced during RNA extraction, cDNA 
synthesis, PCR and UDPS was low. However, for rare variants in vitro 
recombination and effects of sequence direction needs to be considered. Finally, 
the design of primers for PCR amplification is of special importance during UDPS, 
since primer-related selective amplification can skew frequency estimates of 
genetic variants. However, it remains to be investigated if our results can be 
generalized to other gene fragments or longer read length. 
 
In Paper I, we showed that the levels of pre-existing drug resistance in plasma 
samples from five treatment naive patients was very low and that several 
important drug resistance mutations (M184V, Y181C, Y188C and T215Y/F) were 
not detectable in pre-treatment samples, indicating that the natural occurrence of 
these mutations were below our detection limit. However, we found low, but 
significant, levels of M184I (4 of 5 patients), T215I and/or T215A (4 of 5 patients) 
at proportions ranging from 0.02%–0.12%. The clinical significance of these 
mutations is probably low. It has been shown that pre-existing M184I does not 
necessarily lead to virologic failure [212] and that the T215I/A mutations do not 
by them self confer phenotypic resistance [186]. 
 
During treatment failure and treatment interruption, we found almost 100% 
replacement of wild-type and drug-resistant variants, respectively (Paper I). This 
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implies that the proportion of minority variants with drug resistance in patients 
with previous treatment failure can be too low to be detectible even with highly 
sensitive UDPS technology. For optimal treatment management of such patients it 
would be interesting to investigate the utility of analyzing viral DNA in PBMCs.  
 
In Paper III, three patients with HIV-1 populations that switched coreceptor use 
were investigated. UDPS analysis showed that X4 virus that emerged after 
coreceptor switch was not detected during PHI and that the X4 population most 
probably evolved from the R5 population during the course of infection rather 
than was transmitted as minor variants. Moreover, one to three major variants 
were found during PHI, lending support to the hypothesis that infection usually is 
established with one or just a few viral particles [70, 72, 73]. 
 
We have investigated the frequency and type of errors that occurred during UDPS 
(Paper IV). The errors that remained after data cleaning were significantly more 
often transitions than transversions, which indicates that a substantial proportion 
of these errors were introduced during PCR. This affects the limits of detection of 
minority mutations since UDPS analyses of HIV-1 are presided by a PCR step.  
 
To circumvent these errors an improved methodology was developed with the 
intention to allow more accurate detection of minority viral variants. In this 
method each HIV-1 template was given a specific genetic barcode (primer ID) 
prior to the PCR and by subsequently generating at least three sequences from 
each template, consensus sequences with minimal errors can be constructed. 
Recently similar approaches have been described [253, 254]. Our preliminary 
results showed a reduced UDPS error frequency from 0.6% in raw reads to 
0.0006% errors per nucleotide after consensus generation. This improved 
methodology has the potential to increase the sensitivity and accuracy of UDPS 
analyses 1000-fold. Taken together, our studies show that UDPS can be used to 
gain new insights in HIV evolution and resistance and is relevant for the possible 
future clinical use of this technology.  
 
Current routine HIV-1 resistance testing is performed by population Sanger 
sequencing, which has the disadvantage of only detecting mutations present in 
>20% of the virus population. However, it has been shown that minority variants 
below this detection limit may have clinical relevance. This applies especially to 
minority NNRTI mutations [206-212]. Specifically, the presence of minority 
variants representing >0.5% of the viral population conferred a significant higher 
risk of virologic failure compared with minority variants present at less than 0.5% 
[206]. Because NNRTI-based regimens are the most commonly prescribed first-
line therapy, the clinical use of a more sensitive method could help identify 
individuals at increased risk of virologic failure and thereby improve clinical 
management. One solution could be to use a real-time PCR method to detect the 
presence of minority drug resistance mutations. However, due to the high number 
of drug resistance mutations needed to be tested a whole-genome NGS sequencing 
approach might be more cost-effective. Recently, whole genome deep sequencing 
of HIV-1 has been described [252]. This approach could have great potential for 
improving the sensitivity of resistance tests used in the clinic and it is likely that 
Sanger sequencing for HIV-1 drug resistance will be outcompeted relatively soon. 
However, for other application such a single genome sequencing (SGS) [257] of 
samples with low copy number, Sanger sequencing will only be outcompeted 
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when technologies offering longer and more accurate reads have become 
available.  
 
For routine drug resistance testing linkage between mutations in not crucial, thus 
the HIV-1 genome could be randomly fragmented and sequenced on any of the 
NGS platforms. To increase the accuracy of the NGS method it might be advisable 
to combine this method with a primer ID approach to tag individual templates. To 
be able to select which NGS technology would be most suitable several aspects 
needs to be considered, such as sequence depth, evenness of coverage, read 
length, read quality, running costs, simplicity of workflows, total run times and 
scalability. A recent study by Loman et al, compared the three high throughput 
benchtop instruments available today (454 GS junior/Roche, MiSeq/Illumina, Ion 
Torrent/Life Technologies). The MiSeq and Ion Torrent had the highest 
throughput. The 454 GS Junior generated the longest reads and most contiguous 
assemblies but had the lowest throughput. MiSeq had the lowest error rates and 
the Ion Torrent and 454 GS Junior both produced homopolymer-associated indel 
errors. The number of indel errors was higher for Ion Torrent compared with 454 
GS Junior. Moreover, the Ion Torrent had the shortest run time [279]. This study 
demonstrates that each technology has a trade-off between advantages and 
disadvantages.  
 
A NGS approach could be used for routine type/subtype determination of other 
viruses (influenza and HCV) or for investigation outbreaks of bacterial pathogens. 
However, for type/subtype determination the depth does not need to be as great 
as for drug resistance testing instead it is important to generate as good coverage 
of the genome as possible to be able to make a correct assembly of the whole 
genome. This could also be used to determine recombinant virus variants and new 
strains.  
 
The length of the sequence reads becomes crucial for deep sequencing projects 
where individual HIV-1 variants or the linkage between mutations are studied. 
Examples of such studies are: understanding the mechanism behind drug 
resistance development and coreceptor switch or identifying and characterizing 
distinct viral sub-populations in different compartments within HIV-1 patients. 
These kinds of projects are usually more research-based and do not have an 
obvious connection to routine tests in the clinic. The NGS method which allows the 
longest read length is 454 sequencing which allows ~400-500 bases. However, 
the absolute length might vary between different amplicons due to differences in 
nucleotide structure. By sequencing as long reads as possible the risk of 
generating artificial variants are reduced compared with shotgun approaches 
using short reads and assembly algorithms. The accuracy of the 454 assay will be 
improved by the use of a primer ID approach (as described above) to create 
consensus sequences for each template. The potential for the use of the primer IDs 
in deep sequencing studies is high and when the read length of the 454 
sequencing technology increases, this method more and more mimics a SGS 
method but with a high throughput. Nonetheless, to optimally use the primer ID 
approach further investigation is needed to overcome skewness of template 
amplification and optimization of experimental setup to increase recovery. 
Furthermore, methods that allow direct sequencing of cDNA or ideally RNA 
without the need of prior PCR amplification would be the optimal choice for deep 
sequencing projects of HIV-1 especially if errors introduced during sequencing 
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and cDNA synthesis could be removed by e.g. a triplicate sequence of each 
template (similar to the primer ID approach). Today we are only in the beginning 
of exploring the future potential for NGS both in the clinic and in research based 
settings, exiting next coming years are to be expected. Thus, it is very likely 
technological advances will continue to allow better and better insights into the 
evolution of HIV-1 and other pathogens. 
 
 
 
 50 
6 ACKNOWLEDGEMENTS 
 
There are many people that I would like to thank who have contributed to the work in this 
thesis and who have supported in many ways during my time as a PhD Student. 
 
First I would like to say thank you to all patients participating in these studies. Without 
their contribution, this work would not have been possible.  
 
Jan Albert: I am amazed by your knowledge and expertise and I am grateful for having 
been a part of you research team. Thank you for always being available for questions and 
for taking time to discuss my work. Thank you for always being positive and looking at 
research results from the bright side. I am immensely grateful for all the support you have 
shown me during my years as a PhD student. 
 
Mattias Mild: Thank you for becoming my co-supervisor and friend. Thank you for your 
enthusiasm, passions and for sharing your knowledge in HIV and phylogenetics. Thank 
you for all support, great discussions, energy and laughs throughout the years. Thank you 
for encouraging me in times when I needed it! 
 
Joakim Lundeberg: for introducing me to 454 sequencing and for scientific discussions. 
 
Annika Karlsson: for input and scientific discussions and for being my co-supervisor.  
 
Thomas Leitner: for great scientific discussions. Your knowledge and input has been 
very valuable.  
 
Sarah Palmer: You have a true research soul and your enthusiasm and energy for science 
is an inspiration. Thank you for sharing your scientific knowledge and for all talks, dinners 
and fun times. Thank you so much for introducing me to interesting people. 
 
Sven Britton: For showing me Ethiopia, one of the most interesting trips I have ever 
done. Thank you for your friendship and interesting discussions.  
 
Göran Bratt: For introducing me to the clinical work at Venhälsan and letting me meet 
patients.  
 
Richard Neher: for interesting collaborations and valuable scientific discussions. 
 
Mats Nilsson and Lotte Moens: For interesting discussion and fruitful collaborations. 
 
Emilie Hultin, Sara Arroyo Mühr and Carina Eklund: for exceptional guidance and 
support during the 454 GS Junior experiments. 
 
Tomas Johansson in Lund: Thank you for all your advices regarding the 454 titanium 
experiment.  
 
Joakim Esbjörnsson: for sharing your nice illustrations! 
 
To the Jan Albert’s group at SMI. Afsaneh Heidarian, for taking care of the lab and for 
being such a nice person and friend. Kajsa Apéria, for introducing me to P3 lab and all 
your help in the lab. Maria Axelsson, for all support and talks. Marianne Jansson, for all 
support. Lisbeth Löfstrand, your help with the administration has been very valuable.  
 
   51 
Benita Zweygberg Wirgart: For the nice welcoming atmosphere at the clinical 
microbiology department. 
 
Eva Ericsson: I am so grateful that I have got the chance to work with you and I am 
impressed by your organization and lab skills.   
 
My wonderful colleagues and friends. Johanna Brodin, for bringing your bioinformatic 
expertise into the group. Thank you for being a great colleague and for becoming a true 
friend. I hope we will work together again in the future. Wendy Murillo, my Honduran 
friend. Thank you for a true friendship, I have really enjoyed all our lunches, dinners and 
talks. I hope to come and visit you soon in Honduras. Melissa Norström, for your 
friendship, all laughs and for all crazy things we have done together. I hope to see more of 
you soon. Salma Nowroozalizadeh, for your friendship and for all fun things we have 
done together. I hope to see more of you now when you are back in Sthlm! Helena Skar, 
for all your support and help throughout the years, thank you! Carina Perez, for being 
such an inspiring person. Leda Parham, for your friendship. Lina Josefsson, for your 
friendship and all interesting discussion about the future. Thank you for founding The 
PhD club and or letting me be a part of the team. Susanne Eriksson, for crazy shopping 
time in Seattle, I hope we will do more of that in the autumn. Linda Trönnberg, for 
friendship, lunches and dinners.  Alex Heddini, for being my student and for your 
enthusiasm about the project despite the “disaster”. Tara Wahab, for all nice discussions 
and for a great time in Ethiopia. Malin Stoltz, for your friendship. To all the other 
students: Dace Balode, Viktor Dahl and Marcus Buggert: It has been a pleasure to meet 
you and to have lunches and scientific discussions together.  
 
To the other members of The PhD club: Cofounder Therese Högfeldt, for your friendship 
and all your support and long talks. Cecilia Jädert, for great collaboration! I will miss The 
PhD Club and I hope that I always can be part of it somehow  
 
Till alla mina fantastiska och underbara vänner utanför den akademiska världen. Jag kan 
inte nämna alla vid namn för det skulle ha fyllt många sidor men vet att ni alla betyder så 
oerhört mycket för mig, jag har mycket att ta igen med er! Speciellt tack till Emma och 
Joakim för er vänskap och för att ni med glädje har tagit hand om Vilhelm då tiden inte 
har räckt till. Linda Bengtsson för sann vänskap trots långt geografiskt avstånd. Elle, 
Linda S, Maarit, Anna F, Camilla och Sara, jag vill ses mer! 
 
Mona och Göran Gustafsson: Tack för allt ert stöd och för att ni är de bästa 
farföräldrarna i världen för Vilhelm. Jag är så oerhört tacksam för allt som ni har gjort och 
för att jag har fått lära känna er. Utan allt ert stöd hade denna avhandling inte blivit klar 
på många år.  
 
Mamma och pappa: Tack för att ni alltid har trott på mig och låtit mig gå min egen väg. 
Jag älskar er! 
 
Louise: Tänk att vi valde samma spår. Tack för att du kan läsa min tankar och förstår mig 
som bara en tvillingsyster kan göra. Du är min bästa vän! 
 
Petter: Tack för all kärlek! Tack för att du så osjälviskt fixar allt och för att du har tagit alla 
nätter! Tack för att du är världens bästa pappa! Tack för att du har läst min avhandling 
och din hjälp med figurerna! Jag ser fram emot nya spännande äventyr tillsammans, men 
först har jag så klart mycket att ta igen   
 
Vilhelm: Min älskade lille kille, den kärlek jag får från dig är obeskrivlig och gör allt känns 
möjligt.  
 
 52 
7 REFERENCES 
 
1. Gao, F., et al., Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature, 1999. 397(6718): 
p. 436-41. 
2. Gao, F., et al., Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature, 1992. 
358(6386): p. 495-9. 
3. Keele, B.F., et al., Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science, 2006. 
313(5786): p. 523-6. 
4. Worobey, M., et al., Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature, 2008. 
455(7213): p. 661-4. 
5. Korber, B., et al., Timing the ancestor of the HIV-1 pandemic strains. Science, 2000. 288(5472): p. 
1789-96. 
6. CDC, Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men – New York city and 
California. MMWR Morb Mortal Wkly Rep 1981. 30 p. 305-308. 
7. Hymes, K.B., et al., Kaposi's sarcoma in homosexual men-a report of eight cases. Lancet, 1981. 2(8247): 
p. 598-600. 
8. CDC, Update on acquired immune deficiency syndrome (AIDS)--United States. MMWR Morb Mortal 
Wkly Rep, 1982. 31: p. 507-8, 513-4. 
9. CDC, Possible transfusion-associated AIDS. MMWR Morb Mortal Wkly Rep 1982. 31: p. 652-654. 
10. Barre-Sinoussi, F., et al., Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired 
immune deficiency syndrome (AIDS). Science, 1983. 220(4599): p. 868-71. 
11. Holmes, E.C., What does virus evolution tell us about virus origins? J Virol, 2011. 85(11): p. 5247-51. 
12. Nowak, M.A., et al., Antigenic diversity thresholds and the development of AIDS. Science, 1991. 
254(5034): p. 963-9. 
13. Kantor, R., et al., Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral 
therapy. AIDS, 2004. 18(11): p. 1503-11. 
14. Takehisa, J., et al., Origin and biology of simian immunodeficiency virus in wild-living western gorillas. J 
Virol, 2009. 83(4): p. 1635-48. 
15. Lemey, P., et al., Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci U S A, 2003. 
100(11): p. 6588-92. 
16. Worobey, M., et al., Island biogeography reveals the deep history of SIV. Science, 2010. 329(5998): p. 
1487. 
17. de Sousa, J.D., et al., High GUD incidence in the early 20 century created a particularly permissive time 
window for the origin and initial spread of epidemic HIV strains. PLoS One, 2010. 5(4): p. e9936. 
18. UNAIDS, Report on the global aids epidemic 2010. Geneva, 2010. 
19. UNAIDS, AIDS Epidemic Update 2009. Geneva, 2009. 
20. UNAIDS, World AIDS day report 2011. Geneva, 2011. 
21. Skar, H., C. Hedskog, and J. Albert, HIV-1 evolution in relation to molecular epidemiology and 
antiretroviral resistance. Ann N Y Acad Sci, 2011. 1230: p. 108-18. 
22. Freed, E.O., HIV-1 gag proteins: diverse functions in the virus life cycle. Virology, 1998. 251(1): p. 1-15. 
23. Dalgleish, A.G., et al., The CD4 (T4) antigen is an essential component of the receptor for the AIDS 
retrovirus. Nature, 1984. 312(5996): p. 763-7. 
24. Freed, E.O., HIV-1 and the host cell: an intimate association. Trends Microbiol, 2004. 12(4): p. 170-7. 
25. Berger, E.A., P.M. Murphy, and J.M. Farber, Chemokine receptors as HIV-1 coreceptors: roles in viral 
entry, tropism, and disease. Annu Rev Immunol, 1999. 17: p. 657-700. 
26. Hu, W.S. and H.M. Temin, Genetic consequences of packaging two RNA genomes in one retroviral 
particle: pseudodiploidy and high rate of genetic recombination. Proc Natl Acad Sci U S A, 1990. 87(4): 
p. 1556-60. 
27. Balakrishnan, M., et al., Template dimerization promotes an acceptor invasion-induced transfer 
mechanism during human immunodeficiency virus type 1 minus-strand synthesis. J Virol, 2003. 77(8): 
p. 4710-21. 
28. Schroder, A.R., et al., HIV-1 integration in the human genome favors active genes and local hotspots. 
Cell, 2002. 110(4): p. 521-9. 
29. Vatakis, D.N., et al., Immediate activation fails to rescue efficient human immunodeficiency virus 
replication in quiescent CD4+ T cells. J Virol, 2007. 81(7): p. 3574-82. 
30. Plesa, G., et al., Addition of deoxynucleosides enhances human immunodeficiency virus type 1 
integration and 2LTR formation in resting CD4+ T cells. J Virol, 2007. 81(24): p. 13938-42. 
   53 
31. Agosto, L.M., et al., HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated 
with an improved assay for HIV-1 integration. Virology, 2007. 368(1): p. 60-72. 
32. Loisel-Meyer, S., et al., Glut1-mediated glucose transport regulates HIV infection. Proc Natl Acad Sci U S 
A, 2012. 109(7): p. 2549-54. 
33. Rambaut, A., et al., The causes and consequences of HIV evolution. Nat Rev Genet, 2004. 5(1): p. 52-61. 
34. Sodroski, J., et al., Trans-acting transcriptional regulation of human T-cell leukemia virus type III long 
terminal repeat. Science, 1985. 227(4683): p. 171-3. 
35. Strebel, K., Virus-host interactions: role of HIV proteins Vif, Tat, and Rev. AIDS, 2003. 17 Suppl 4: p. 
S25-34. 
36. Virology, F., Fifth edition. 2007. 2: p. 2165. 
37. Mariani, R., et al., Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell, 2003. 114(1): 
p. 21-31. 
38. Chiu, Y.L. and W.C. Greene, The APOBEC3 cytidine deaminases: an innate defensive network opposing 
exogenous retroviruses and endogenous retroelements. Annu Rev Immunol, 2008. 26: p. 317-53. 
39. Newman, E.N., et al., Antiviral function of APOBEC3G can be dissociated from cytidine deaminase 
activity. Curr Biol, 2005. 15(2): p. 166-70. 
40. Jiang, J. and C. Aiken, Maturation-dependent human immunodeficiency virus type 1 particle fusion 
requires a carboxyl-terminal region of the gp41 cytoplasmic tail. J Virol, 2007. 81(18): p. 9999-10008. 
41. Peng, C., et al., Role of human immunodeficiency virus type 1-specific protease in core protein 
maturation and viral infectivity. J Virol, 1989. 63(6): p. 2550-6. 
42. Vogt, V.M., Proteolytic processing and particle maturation. Curr Top Microbiol Immunol, 1996. 214: p. 
95-131. 
43. Mansky, L.M. and H.M. Temin, Lower in vivo mutation rate of human immunodeficiency virus type 1 
than that predicted from the fidelity of purified reverse transcriptase. J Virol, 1995. 69(8): p. 5087-94. 
44. Abram, M.E., et al., Nature, position, and frequency of mutations made in a single cycle of HIV-1 
replication. J Virol, 2010. 84(19): p. 9864-78. 
45. Drake, J.W., et al., Rates of spontaneous mutation. Genetics, 1998. 148(4): p. 1667-86. 
46. Zhuang, J., et al., Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot 
spots. J Virol, 2002. 76(22): p. 11273-82. 
47. Jetzt, A.E., et al., High rate of recombination throughout the human immunodeficiency virus type 1 
genome. J Virol, 2000. 74(3): p. 1234-40. 
48. Levy, D.N., et al., Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A, 
2004. 101(12): p. 4204-9. 
49. Neher, R.A. and T. Leitner, Recombination rate and selection strength in HIV intra-patient evolution. 
PLoS Comput Biol, 2010. 6(1): p. e1000660. 
50. Ho, D.D., et al., Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 1995. 
373(6510): p. 123-6. 
51. Perelson, A.S., et al., HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral 
generation time. Science, 1996. 271(5255): p. 1582-6. 
52. Ho, D.D., Perspectives series: host/pathogen interactions. Dynamics of HIV-1 replication in vivo. J Clin 
Invest, 1997. 99(11): p. 2565-7. 
53. Allen, T.M., et al., Selective escape from CD8+ T-cell responses represents a major driving force of 
human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 
evolution. J Virol, 2005. 79(21): p. 13239-49. 
54. Frost, S.D., et al., Neutralizing antibody responses drive the evolution of human immunodeficiency virus 
type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A, 2005. 102(51): p. 18514-9. 
55. Van Heuverswyn, F., et al., Human immunodeficiency viruses: SIV infection in wild gorillas. Nature, 
2006. 444(7116): p. 164. 
56. Robertson, D.L., et al., HIV-1 nomenclature proposal. Science, 2000. 288(5463): p. 55-6. 
57. Woodman, Z. and C. Williamson, HIV molecular epidemiology: transmission and adaptation to human 
populations. Curr Opin HIV AIDS, 2009. 4(4): p. 247-52. 
58. Holder, M. and P.O. Lewis, Phylogeny estimation: traditional and Bayesian approaches. Nat Rev Genet, 
2003. 4(4): p. 275-84. 
59. Posada, D., jModelTest: phylogenetic model averaging. Mol Biol Evol, 2008. 25(7): p. 1253-6. 
60. Tamura, K., et al., MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol 
Biol Evol, 2007. 24(8): p. 1596-9. 
61. Guindon, S., Bayesian estimation of divergence times from large sequence alignments. Mol Biol Evol, 
2010. 27(8): p. 1768-81. 
62. Anisimova, M. and O. Gascuel, Approximate likelihood-ratio test for branches: A fast, accurate, and 
powerful alternative. Syst Biol, 2006. 55(4): p. 539-52. 
 54 
63. Gray, R.H., et al., Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-
discordant couples in Rakai, Uganda. Lancet, 2001. 357(9263): p. 1149-53. 
64. Cohen, M.S., et al., Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med, 2011. 
365(6): p. 493-505. 
65. Fang, C.T., et al., Decreased HIV transmission after a policy of providing free access to highly active 
antiretroviral therapy in Taiwan. J Infect Dis, 2004. 190(5): p. 879-85. 
66. Bunnell, R., et al., Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy 
and prevention interventions in rural Uganda. AIDS, 2006. 20(1): p. 85-92. 
67. Zhu, T., et al., Genotypic and phenotypic characterization of HIV-1 patients with primary infection. 
Science, 1993. 261(5125): p. 1179-81. 
68. Zhang, L.Q., et al., Selection for specific sequences in the external envelope protein of human 
immunodeficiency virus type 1 upon primary infection. J Virol, 1993. 67(6): p. 3345-56. 
69. Fischer, W., et al., Transmission of single HIV-1 genomes and dynamics of early immune escape revealed 
by ultra-deep sequencing. PLoS One, 2010. 5(8): p. e12303. 
70. Keele, B.F., et al., Identification and characterization of transmitted and early founder virus envelopes 
in primary HIV-1 infection. Proc Natl Acad Sci U S A, 2008. 105(21): p. 7552-7. 
71. Kearney, M., et al., Human immunodeficiency virus type 1 population genetics and adaptation in newly 
infected individuals. J Virol, 2009. 83(6): p. 2715-27. 
72. Herbeck, J.T., et al., Demographic processes affect HIV-1 evolution in primary infection before the onset 
of selective processes. J Virol, 2011. 85(15): p. 7523-34. 
73. Salazar-Gonzalez, J.F., et al., Genetic identity, biological phenotype, and evolutionary pathways of 
transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med, 2009. 206(6): p. 1273-89. 
74. Masharsky, A.E., et al., A substantial transmission bottleneck among newly and recently HIV-1-infected 
injection drug users in St Petersburg, Russia. J Infect Dis, 2010. 201(11): p. 1697-702. 
75. Nowak, P., et al., The selection and evolution of viral quasispecies in HIV-1 infected children. HIV Med, 
2002. 3(1): p. 1-11. 
76. Kouyos, R.D., et al., Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a 
marker for viral diversity and the age of infection. Clin Infect Dis, 2011. 52(4): p. 532-9. 
77. Schuitemaker, H., A.B. van 't Wout, and P. Lusso, Clinical significance of HIV-1 coreceptor usage. J 
Transl Med, 2011. 9 Suppl 1: p. S5. 
78. Shankarappa, R., et al., Consistent viral evolutionary changes associated with the progression of human 
immunodeficiency virus type 1 infection. J Virol, 1999. 73(12): p. 10489-502. 
79. Williamson, S., et al., A statistical characterization of consistent patterns of human immunodeficiency 
virus evolution within infected patients. Mol Biol Evol, 2005. 22(3): p. 456-68. 
80. Lee, H.Y., et al., Modeling sequence evolution in acute HIV-1 infection. J Theor Biol, 2009. 261(2): p. 
341-60. 
81. Fiebig, E.W., et al., Dynamics of HIV viremia and antibody seroconversion in plasma donors: 
implications for diagnosis and staging of primary HIV infection. AIDS, 2003. 17(13): p. 1871-9. 
82. Hladik, F., et al., Initial events in establishing vaginal entry and infection by human immunodeficiency 
virus type-1. Immunity, 2007. 26(2): p. 257-70. 
83. Boggiano, C. and D.R. Littman, HIV's vagina travelogue. Immunity, 2007. 26(2): p. 145-7. 
84. Mattapallil, J.J., et al., Massive infection and loss of memory CD4+ T cells in multiple tissues during acute 
SIV infection. Nature, 2005. 434(7037): p. 1093-7. 
85. Li, Q., et al., Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T 
cells. Nature, 2005. 434(7037): p. 1148-52. 
86. Arthos, J., et al., HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut 
mucosal homing receptor for peripheral T cells. Nat Immunol, 2008. 9(3): p. 301-9. 
87. McMichael, A.J., et al., The immune response during acute HIV-1 infection: clues for vaccine 
development. Nat Rev Immunol, 2010. 10(1): p. 11-23. 
88. Mellors, J.W., et al., Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science, 
1996. 272(5265): p. 1167-70. 
89. Fraser, C., et al., Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary 
hypothesis. Proc Natl Acad Sci U S A, 2007. 104(44): p. 17441-6. 
90. Lifson, A.R., et al., Long-term human immunodeficiency virus infection in asymptomatic homosexual 
and bisexual men with normal CD4+ lymphocyte counts: immunologic and virologic characteristics. J 
Infect Dis, 1991. 163(5): p. 959-65. 
91. O'Brien, S.J. and G.W. Nelson, Human genes that limit AIDS. Nat Genet, 2004. 36(6): p. 565-74. 
92. Hutter, G., et al., Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J 
Med, 2009. 360(7): p. 692-8. 
   55 
93. Piacentini, L., et al., Genetic correlates of protection against HIV infection: the ally within. J Intern Med, 
2009. 265(1): p. 110-24. 
94. Goonetilleke, N., et al., The first T cell response to transmitted/founder virus contributes to the control 
of acute viremia in HIV-1 infection. J Exp Med, 2009. 206(6): p. 1253-72. 
95. Streeck, H., et al., Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary 
infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol, 2009. 83(15): p. 
7641-8. 
96. Tomaras, G.D., et al., Initial B-cell responses to transmitted human immunodeficiency virus type 1: 
virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies 
with ineffective control of initial viremia. J Virol, 2008. 82(24): p. 12449-63. 
97. Albert, J., et al., Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 
infection and consequent emergence of virus variants which resist neutralization by autologous sera. 
AIDS, 1990. 4(2): p. 107-12. 
98. Richman, D.D., et al., Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc 
Natl Acad Sci U S A, 2003. 100(7): p. 4144-9. 
99. Wei, X., et al., Antibody neutralization and escape by HIV-1. Nature, 2003. 422(6929): p. 307-12. 
100. Dhillon, A.K., et al., Dissecting the neutralizing antibody specificities of broadly neutralizing sera from 
human immunodeficiency virus type 1-infected donors. J Virol, 2007. 81(12): p. 6548-62. 
101. Feng, Y., et al., HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-
coupled receptor. Science, 1996. 272(5263): p. 872-7. 
102. Choe, H., et al., The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 
isolates. Cell, 1996. 85(7): p. 1135-48. 
103. Deng, H., et al., Identification of a major co-receptor for primary isolates of HIV-1. Nature, 1996. 
381(6584): p. 661-6. 
104. Doranz, B.J., et al., A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors 
CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell, 1996. 85(7): p. 1149-58. 
105. Dragic, T., et al., HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature, 
1996. 381(6584): p. 667-73. 
106. Lusso, P., HIV and the chemokine system: 10 years later. EMBO J, 2006. 25(3): p. 447-56. 
107. Chalmet, K., et al., Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: 
correlates and evidence for transmission. J Infect Dis, 2012. 205(2): p. 174-84. 
108. Grivel, J.C., R.J. Shattock, and L.B. Margolis, Selective transmission of R5 HIV-1 variants: where is the 
gatekeeper? J Transl Med, 2011. 9 Suppl 1: p. S6. 
109. Hedskog, C., M. Mild, and J. Albert, Transmission of the X4 phenotype of HIV-1: is there evidence against 
the "random transmission" hypothesis? J Infect Dis, 2012. 205(2): p. 163-5. 
110. Karlsson, A., et al., MT-2 cell tropism as prognostic marker for disease progression in human 
immunodeficiency virus type 1 infection. J Clin Microbiol, 1994. 32(2): p. 364-70. 
111. Koot, M., et al., Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion 
and progression to AIDS. Ann Intern Med, 1993. 118(9): p. 681-8. 
112. Esbjornsson, J., et al., Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage 
disease--indication of an evolving epidemic in West Africa. Retrovirology, 2010. 7: p. 23. 
113. Connor, R.I., et al., Change in coreceptor use correlates with disease progression in HIV-1--infected 
individuals. J Exp Med, 1997. 185(4): p. 621-8. 
114. Scarlatti, G., et al., In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated 
suppression. Nat Med, 1997. 3(11): p. 1259-65. 
115. Asjo, B., et al., Replicative capacity of human immunodeficiency virus from patients with varying 
severity of HIV infection. Lancet, 1986. 2(8508): p. 660-2. 
116. Fenyo, E.M., et al., Distinct replicative and cytopathic characteristics of human immunodeficiency virus 
isolates. J Virol, 1988. 62(11): p. 4414-9. 
117. Cheng-Mayer, C., et al., Biologic features of HIV-1 that correlate with virulence in the host. Science, 
1988. 240(4848): p. 80-2. 
118. Schuitemaker, H., et al., Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants 
detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in 
primary T-cell culture. J Virol, 1991. 65(1): p. 356-63. 
119. Tersmette, M., et al., Differential syncytium-inducing capacity of human immunodeficiency virus 
isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency 
syndrome (AIDS) and AIDS-related complex. J Virol, 1988. 62(6): p. 2026-32. 
120. Tersmette, M., et al., Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the 
pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol, 1989. 
63(5): p. 2118-25. 
 56 
121. Moore, J.P., et al., The CCR5 and CXCR4 coreceptors--central to understanding the transmission and 
pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses, 2004. 
20(1): p. 111-26. 
122. Baggiolini, M., B. Dewald, and B. Moser, Human chemokines: an update. Annu Rev Immunol, 1997. 15: 
p. 675-705. 
123. Rollins, B.J., Chemokines. Blood, 1997. 90(3): p. 909-28. 
124. Amara, A., et al., HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent 
internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med, 
1997. 186(1): p. 139-46. 
125. Oberlin, E., et al., The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-
cell-line-adapted HIV-1. Nature, 1996. 382(6594): p. 833-5. 
126. Bagnarelli, P., et al., Host-specific modulation of the selective constraints driving human 
immunodeficiency virus type 1 env gene evolution. J Virol, 1999. 73(5): p. 3764-77. 
127. Carrillo, A. and L. Ratner, Cooperative effects of the human immunodeficiency virus type 1 envelope 
variable loops V1 and V3 in mediating infectivity for T cells. J Virol, 1996. 70(2): p. 1310-6. 
128. Jansson, M., et al., Length variation of glycoprotein 120 V2 region in relation to biological phenotypes 
and coreceptor usage of primary HIV type 1 isolates. AIDS Res Hum Retroviruses, 2001. 17(15): p. 
1405-14. 
129. Labrosse, B., et al., Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 
gp120 for interaction with the CXCR4 receptor. J Virol, 2001. 75(12): p. 5457-64. 
130. Edinger, A.L., et al., Differential utilization of CCR5 by macrophage and T cell tropic simian 
immunodeficiency virus strains. Proc Natl Acad Sci U S A, 1997. 94(8): p. 4005-10. 
131. Stamatatos, L., M. Wiskerchen, and C. Cheng-Mayer, Effect of major deletions in the V1 and V2 loops of 
a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. AIDS Res 
Hum Retroviruses, 1998. 14(13): p. 1129-39. 
132. Shioda, T., J.A. Levy, and C. Cheng-Mayer, Small amino acid changes in the V3 hypervariable region of 
gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc 
Natl Acad Sci U S A, 1992. 89(20): p. 9434-8. 
133. De Jong, J.J., et al., Minimal requirements for the human immunodeficiency virus type 1 V3 domain to 
support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol, 1992. 
66(11): p. 6777-80. 
134. Thordsen, I., S. Polzer, and M. Schreiber, Infection of cells expressing CXCR4 mutants lacking N-
glycosylation at the N-terminal extracellular domain is enhanced for R5X4-dualtropic human 
immunodeficiency virus type-1. BMC Infect Dis, 2002. 2: p. 31. 
135. Fouchier, R.A., et al., Phenotype-associated sequence variation in the third variable domain of the 
human immunodeficiency virus type 1 gp120 molecule. J Virol, 1992. 66(5): p. 3183-7. 
136. Hu, Q., et al., Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 
utilization. J Mol Biol, 2000. 302(2): p. 359-75. 
137. Mild, M., et al., Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-
switch (R5-tropic only) HIV-1 populations during infection. Infect Genet Evol, 2010. 10(3): p. 356-64. 
138. Li, Y., et al., Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in 
CD4 binding. J Virol, 1993. 67(1): p. 584-8. 
139. Pollakis, G., et al., N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major 
determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem, 2001. 276(16): p. 13433-41. 
140. Derdeyn, C.A., et al., Envelope-constrained neutralization-sensitive HIV-1 after heterosexual 
transmission. Science, 2004. 303(5666): p. 2019-22. 
141. Berger, E.A., et al., A new classification for HIV-1. Nature, 1998. 391(6664): p. 240. 
142. Koot, M., et al., HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 
cocultivation assay. AIDS, 1992. 6(1): p. 49-54. 
143. Whitcomb, J.M., et al., Development and characterization of a novel single-cycle recombinant-virus 
assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents 
Chemother, 2007. 51(2): p. 566-75. 
144. Su, Z., et al., Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-
sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis, 2009. 
200(11): p. 1724-8. 
145. Raymond, S., et al., Development and performance of a new recombinant virus phenotypic entry assay 
to determine HIV-1 coreceptor usage. J Clin Virol, 2010. 47(2): p. 126-30. 
146. de Mendoza, C., et al., Performance of a population-based HIV-1 tropism phenotypic assay and 
correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters. J Acquir Immune Defic 
Syndr, 2008. 48(3): p. 241-4. 
   57 
147. Poveda, E., et al., Design and validation of new genotypic tools for easy and reliable estimation of HIV 
tropism before using CCR5 antagonists. J Antimicrob Chemother, 2009. 63(5): p. 1006-10. 
148. Seclen, E., et al., High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-
experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother, 2010. 
65(7): p. 1486-92. 
149. Jensen, M.A. and A.B. van 't Wout, Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev, 
2003. 5(2): p. 104-12. 
150. Lengauer, T., et al., Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol, 2007. 25(12): p. 
1407-10. 
151. Vandekerckhove, L.P., et al., European guidelines on the clinical management of HIV-1 tropism testing. 
Lancet Infect Dis, 2011. 11(5): p. 394-407. 
152. Harrigan, P.R., Screening for HIV tropism using population-based V3 genotypic analysis: a retrospective 
virological outcome analysis using stored plasma screening samples from MOTIVATE-1. 5th IAS 
Conference on HIV Pathogenesis and Treatment, 2009. Abstract no. WELBA101  
153. Garrido, C., et al., Evaluation of eight different bioinformatics tools to predict viral tropism in different 
human immunodeficiency virus type 1 subtypes. J Clin Microbiol, 2008. 46(3): p. 887-91. 
154. Raymond, S., et al., Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep 
pyrosequencing. AIDS, 2011. 25(13): p. 1668-70. 
155. Furman, P.A. and D.W. Barry, Spectrum of antiviral activity and mechanism of action of zidovudine. An 
overview. Am J Med, 1988. 85(2A): p. 176-81. 
156. Richman, D.D., HIV chemotherapy. Nature, 2001. 410(6831): p. 995-1001. 
157. Collier, A.C., et al., Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, 
and zalcitabine. AIDS Clinical Trials Group. N Engl J Med, 1996. 334(16): p. 1011-7. 
158. D'Aquila, R.T., et al., Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine 
in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute 
of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern 
Med, 1996. 124(12): p. 1019-30. 
159. Staszewski, S., et al., Virological and immunological analysis of a triple combination pilot study with 
loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS, 1996. 10(5): p. F1-7. 
160. Sharkey, M., et al., In vivo evidence for instability of episomal human immunodeficiency virus type 1 
cDNA. J Virol, 2005. 79(8): p. 5203-10. 
161. Bailey, J.R., et al., Residual human immunodeficiency virus type 1 viremia in some patients on 
antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating 
CD4+ T cells. J Virol, 2006. 80(13): p. 6441-57. 
162. Kieffer, T.L., et al., Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production 
without evolution in treated adults with undetectable HIV loads. J Infect Dis, 2004. 189(8): p. 1452-65. 
163. Nettles, R.E., et al., Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. 
JAMA, 2005. 293(7): p. 817-29. 
164. Maldarelli, F., et al., ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy 
viremia. PLoS Pathog, 2007. 3(4): p. e46. 
165. Butler, S.L., E.P. Johnson, and F.D. Bushman, Human immunodeficiency virus cDNA metabolism: 
notable stability of two-long terminal repeat circles. J Virol, 2002. 76(8): p. 3739-47. 
166. Pierson, T.C., et al., Intrinsic stability of episomal circles formed during human immunodeficiency virus 
type 1 replication. J Virol, 2002. 76(8): p. 4138-44. 
167. Shen, L. and R.F. Siliciano, Viral reservoirs, residual viremia, and the potential of highly active 
antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol, 2008. 122(1): p. 22-8. 
168. St Clair, M.H., et al., 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified 
human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother, 1987. 31(12): p. 
1972-7. 
169. Kohlstaedt, L.A., et al., Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed 
with an inhibitor. Science, 1992. 256(5065): p. 1783-90. 
170. Kempf, D.J., et al., Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus 
protease by coadministration with ritonavir. Antimicrob Agents Chemother, 1997. 41(3): p. 654-60. 
171. Wild, C.T., et al., Peptides corresponding to a predictive alpha-helical domain of human 
immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A, 
1994. 91(21): p. 9770-4. 
172. Matos, P.M., M.A. Castanho, and N.C. Santos, HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 
interact with erythrocyte and lymphocyte membranes. PLoS One, 2010. 5(3): p. e9830. 
173. Palani, A. and J.R. Tagat, Discovery and development of small-molecule chemokine coreceptor CCR5 
antagonists. J Med Chem, 2006. 49(10): p. 2851-7. 
 58 
174. Dorr, P., et al., Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule 
inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 
activity. Antimicrob Agents Chemother, 2005. 49(11): p. 4721-32. 
175. Espeseth, A.S., et al., HIV-1 integrase inhibitors that compete with the target DNA substrate define a 
unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A, 2000. 97(21): p. 11244-9. 
176. Hazuda, D.J., et al., A naphthyridine carboxamide provides evidence for discordant resistance between 
mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A, 2004. 101(31): p. 
11233-8. 
177. Finzi, D., et al., Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. 
Science, 1997. 278(5341): p. 1295-300. 
178. Zhang, Z., et al., Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T 
cells. Science, 1999. 286(5443): p. 1353-7. 
179. Smith, B.A., et al., Persistence of infectious HIV on follicular dendritic cells. J Immunol, 2001. 166(1): p. 
690-6. 
180. Popov, S., et al., Long-term productive human immunodeficiency virus infection of CD1a-sorted myeloid 
dendritic cells. J Virol, 2005. 79(1): p. 602-8. 
181. Kalter, D.C., et al., Epidermal Langerhans cells are not principal reservoirs of virus in HIV disease. J 
Immunol, 1991. 146(10): p. 3396-404. 
182. Siliciano, J.D., et al., Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in 
resting CD4+ T cells. Nat Med, 2003. 9(6): p. 727-8. 
183. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 
http://aidsinfo.nih.gov, 2011. 
184. The European AIDS Clinical Society. www.europeanaidsclinicalsociety.org, 2011. 
185. The Swedish guidelines for antiviral therapy www.smittskyddsinstitutet.se/rav, 2011. 
186. Wensing, A.M. and C.A. Boucher, Worldwide transmission of drug-resistant HIV. AIDS Rev, 2003. 5(3): 
p. 140-55. 
187. Boucher, C.A., et al., Ordered appearance of zidovudine resistance mutations during treatment of 18 
human immunodeficiency virus-positive subjects. J Infect Dis, 1992. 165(1): p. 105-10. 
188. Gardner, E.M., et al., Antiretroviral medication adherence and the development of class-specific 
antiretroviral resistance. AIDS, 2009. 23(9): p. 1035-46. 
189. Llibre, J.M., J.M. Schapiro, and B. Clotet, Clinical implications of genotypic resistance to the newer 
antiretroviral drugs in HIV-1-infected patients with virological failure. Clin Infect Dis, 2010. 50(6): p. 
872-81. 
190. Hogg, R.S., et al., Emergence of drug resistance is associated with an increased risk of death among 
patients first starting HAART. PLoS Med, 2006. 3(9): p. e356. 
191. Johnson, V.A., et al., Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med, 
2010. 18(5): p. 156-63. 
192. Schinazi, R.F., et al., Characterization of human immunodeficiency viruses resistant to oxathiolane-
cytosine nucleosides. Antimicrob Agents Chemother, 1993. 37(4): p. 875-81. 
193. Quan, Y., et al., Endogenous reverse transcription assays reveal high-level resistance to the triphosphate 
of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1. J Virol, 1996. 
70(8): p. 5642-5. 
194. Meyer, P.R., et al., Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a 
nucleotide-dependent mechanism. Proc Natl Acad Sci U S A, 1998. 95(23): p. 13471-6. 
195. Arion, D., et al., Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): 
increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral 
reverse transcriptase. Biochemistry, 1998. 37(45): p. 15908-17. 
196. Larder, B.A. and S.D. Kemp, Multiple mutations in HIV-1 reverse transcriptase confer high-level 
resistance to zidovudine (AZT). Science, 1989. 246(4934): p. 1155-8. 
197. Bacheler, L.T., et al., Human immunodeficiency virus type 1 mutations selected in patients failing 
efavirenz combination therapy. Antimicrob Agents Chemother, 2000. 44(9): p. 2475-84. 
198. Demeter, L.M., et al., Delavirdine susceptibilities and associated reverse transcriptase mutations in 
human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine 
monotherapy (ACTG 260). Antimicrob Agents Chemother, 2000. 44(3): p. 794-7. 
199. Deeks, S.G., International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase 
inhibitor resistance. J Acquir Immune Defic Syndr, 2001. 26 Suppl 1: p. S25-33. 
200. Dykes, C., et al., Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 
drug-resistant mutants. Virology, 2001. 285(2): p. 193-203. 
201. Arts, E.J. and D.J. Hazuda, HIV-1 Antiretroviral Drug Therapy. Cold Spring Harb Perspect Med, 2012. 
2(4): p. a007161. 
   59 
202. Tebit, D.M., et al., Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: 
impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors. J Virol, 2010. 84(19): p. 
9817-30. 
203. Molla, A., et al., Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat 
Med, 1996. 2(7): p. 760-6. 
204. Westby, M., et al., Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral 
strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol, 
2007. 81(5): p. 2359-71. 
205. Coffin, J.M., HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and 
therapy. Science, 1995. 267(5197): p. 483-9. 
206. Li, J.Z., et al., Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral 
treatment failure: a systematic review and pooled analysis. JAMA, 2011. 305(13): p. 1327-35. 
207. Simen, B.B., et al., Low-abundance drug-resistant viral variants in chronically HIV-infected, 
antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis, 2009. 
199(5): p. 693-701. 
208. Balduin, M., et al., Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in 
therapy-naive patients and their impact on the virological failure. J Clin Virol, 2009. 45(1): p. 34-8. 
209. Paredes, R., et al., Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of 
antiretroviral treatment failure. J Infect Dis, 2010. 201(5): p. 662-71. 
210. Johnson, J.A., et al., Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-
naive populations and associate with reduced treatment efficacy. PLoS Med, 2008. 5(7): p. e158. 
211. Geretti, A.M., et al., Low-frequency K103N strengthens the impact of transmitted drug resistance on 
virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J 
Acquir Immune Defic Syndr, 2009. 52(5): p. 569-73. 
212. Metzner, K.J., et al., Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in 
treatment-naive and -adherent patients. Clin Infect Dis, 2009. 48(2): p. 239-47. 
213. Metzner, K.J., et al., Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 
variants in chronically HIV-1 infected, treatment-naive patients. J Clin Virol, 2011. 50(2): p. 156-61. 
214. Messiaen, P., et al., Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-
based regimen in treatment-naive patients. Virology, 2012. 426(1): p. 7-11. 
215. Goodman, D.D., et al., Low level of the K103N HIV-1 above a threshold is associated with virological 
failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS, 2011. 25(3): p. 
325-33. 
216. Metzner, K.J., et al., Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present 
at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J 
Infect Dis, 2010. 201(7): p. 1063-71. 
217. Archer, J., et al., The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants 
through time--an ultra-deep approach. PLoS Comput Biol, 2010. 6(12): p. e1001022. 
218. UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study; UK Register of HIV 
Seroconverters.Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom AIDS, 
2007. 21: p. 1035–1039. 
219. Yerly, S., et al., Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology 
survey. AIDS, 2007. 21(16): p. 2223-9. 
220. SPREAD programme. Transmission of drug-resistant HIV-1 in Europé remains limited to single classes. 
AIDS, 2008. 22: p. 625–635. 
221. Karlsson, A., et al., Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-
1 infection in Sweden 2003-2010. PLoS One, 2012. 7(3): p. e33484. 
222. Vercauteren, J., et al., Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis, 2009. 
200(10): p. 1503-8. 
223. Yerly, S., et al., Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 
reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol, 1998. 
72(5): p. 3520-3. 
224. Gandhi, R.T., et al., Progressive reversion of human immunodeficiency virus type 1 resistance mutations 
in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis, 2003. 37(12): p. 1693-8. 
225. Little, S.J., et al., Persistence of transmitted drug resistance among subjects with primary human 
immunodeficiency virus infection. J Virol, 2008. 82(11): p. 5510-8. 
226. Lindstrom, A., et al., HIV-1 transmission cluster with M41L 'singleton' mutation and decreased 
transmission of resistance in newly diagnosed Swedish homosexual men. Antivir Ther, 2006. 11(8): p. 
1031-9. 
 60 
227. Pingen, M., et al., Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother, 
2011. 66(7): p. 1467-80. 
228. Hedskog, C., et al., Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep 
pyrosequencing. PLoS One, 2010. 5(7): p. e11345. 
229. Joos, B., et al., HIV rebounds from latently infected cells, rather than from continuing low-level 
replication. Proc Natl Acad Sci U S A, 2008. 105(43): p. 16725-30. 
230. Diaz, R.S., et al., Similar efficacy of lopinavir/ritonavir-containing regimens among clades B and F HIV-
1-Infected individuals in Brazil. J Acquir Immune Defic Syndr, 2008. 47(3): p. 399-401. 
231. Jourdain, G., et al., Association between detection of HIV-1 DNA resistance mutations by a sensitive 
assay at initiation of antiretroviral therapy and virologic failure. Clin Infect Dis, 2010. 50(10): p. 1397-
404. 
232. Sanger, F. and A.R. Coulson, A rapid method for determining sequences in DNA by primed synthesis with 
DNA polymerase. J Mol Biol, 1975. 94(3): p. 441-8. 
233. Metzker, M.L., Sequencing technologies - the next generation. Nat Rev Genet, 2010. 11(1): p. 31-46. 
234. Dressman, D., et al., Transforming single DNA molecules into fluorescent magnetic particles for 
detection and enumeration of genetic variations. Proc Natl Acad Sci U S A, 2003. 100(15): p. 8817-22. 
235. Fedurco, M., et al., BTA, a novel reagent for DNA attachment on glass and efficient generation of solid-
phase amplified DNA colonies. Nucleic Acids Res, 2006. 34(3): p. e22. 
236. Hoffmann, C., et al., DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. 
Nucleic Acids Res, 2007. 35(13): p. e91. 
237. Wang, G.P., et al., HIV integration site selection: analysis by massively parallel pyrosequencing reveals 
association with epigenetic modifications. Genome Res, 2007. 17(8): p. 1186-94. 
238. Varghese, V., et al., Minority variants associated with transmitted and acquired HIV-1 nonnucleoside 
reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside 
reverse transcriptase inhibitors. J Acquir Immune Defic Syndr, 2009. 52(3): p. 309-15. 
239. Ronaghi, M., M. Uhlen, and P. Nyren, A sequencing method based on real-time pyrophosphate. Science, 
1998. 281(5375): p. 363, 365. 
240. Rozera, G., et al., Archived HIV-1 minority variants detected by ultra-deep pyrosequencing in provirus 
may be fully replication competent. AIDS, 2009. 23(18): p. 2541-3. 
241. Tsibris, A.M., et al., Quantitative deep sequencing reveals dynamic HIV-1 escape and large population 
shifts during CCR5 antagonist therapy in vivo. PLoS One, 2009. 4(5): p. e5683. 
242. Zagordi, O., et al., Error correction of next-generation sequencing data and reliable estimation of HIV 
quasispecies. Nucleic Acids Res, 2010. 38(21): p. 7400-9. 
243. Zagordi, O., et al., ShoRAH: estimating the genetic diversity of a mixed sample from next-generation 
sequencing data. BMC Bioinformatics, 2011. 12: p. 119. 
244. Archer, J., et al., Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-
using HIV-1 with ultra-deep pyrosequencing. AIDS, 2009. 23(10): p. 1209-18. 
245. De Grassi, A., et al., Ultradeep sequencing of a human ultraconserved region reveals somatic and 
constitutional genomic instability. PLoS Biol, 2010. 8(1): p. e1000275. 
246. Campbell, P.J., et al., Identification of somatically acquired rearrangements in cancer using genome-
wide massively parallel paired-end sequencing. Nat Genet, 2008. 40(6): p. 722-9. 
247. Le, T., et al., Low-abundance HIV drug-resistant viral variants in treatment-experienced persons 
correlate with historical antiretroviral use. PLoS One, 2009. 4(6): p. e6079. 
248. Mitsuya, Y., et al., Minority human immunodeficiency virus type 1 variants in antiretroviral-naive 
persons with reverse transcriptase codon 215 revertant mutations. J Virol, 2008. 82(21): p. 10747-55. 
249. Wang, C., et al., Characterization of mutation spectra with ultra-deep pyrosequencing: application to 
HIV-1 drug resistance. Genome Res, 2007. 17(8): p. 1195-201. 
250. Knoepfel, S.A., et al., In-depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by 
endogenous APOBEC3 proteins using massively parallel sequencing. J Virol Methods, 2011. 171(2): p. 
329-38. 
251. Poon, A.F., et al., Phylogenetic analysis of population-based and deep sequencing data to identify 
coevolving sites in the nef gene of HIV-1. Mol Biol Evol, 2010. 27(4): p. 819-32. 
252. Henn, M.R., et al., Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants 
upon immune recognition during acute infection. PLoS Pathog, 2012. 8(3): p. e1002529. 
253. Jabara, C.B., et al., Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer 
ID. Proc Natl Acad Sci U S A, 2011. 108(50): p. 20166-71. 
254. Kinde, I., et al., Detection and quantification of rare mutations with massively parallel sequencing. Proc 
Natl Acad Sci U S A, 2011. 108(23): p. 9530-5. 
255. Shafer, R.W., Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant 
diagnostic and therapeutic options. J Infect Dis, 2009. 199(5): p. 610-2. 
   61 
256. Rozera, G., et al., Massively parallel pyrosequencing highlights minority variants in the HIV-1 env 
quasispecies deriving from lymphomonocyte sub-populations. Retrovirology, 2009. 6: p. 15. 
257. Palmer, S., et al., Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in 
treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol, 2005. 
43(1): p. 406-13. 
258. Gianella, S., et al., Detection of minority resistance during early HIV-1 infection: natural variation and 
spurious detection rather than transmission and evolution of multiple viral variants. J Virol, 2011. 
85(16): p. 8359-67. 
259. Kanagawa, T., Bias and artifacts in multitemplate polymerase chain reactions (PCR). J Biosci Bioeng, 
2003. 96(4): p. 317-23. 
260. Meyerhans, A., J.P. Vartanian, and S. Wain-Hobson, DNA recombination during PCR. Nucleic Acids Res, 
1990. 18(7): p. 1687-91. 
261. Salazar-Gonzalez, J.F., et al., Deciphering human immunodeficiency virus type 1 transmission and early 
envelope diversification by single-genome amplification and sequencing. J Virol, 2008. 82(8): p. 3952-
70. 
262. Judo, M.S., A.B. Wedel, and C. Wilson, Stimulation and suppression of PCR-mediated recombination. 
Nucleic Acids Res, 1998. 26(7): p. 1819-25. 
263. Lahr, D.J. and L.A. Katz, Reducing the impact of PCR-mediated recombination in molecular evolution 
and environmental studies using a new-generation high-fidelity DNA polymerase. Biotechniques, 2009. 
47(4): p. 857-66. 
264. Diallo, K., M. Gotte, and M.A. Wainberg, Molecular impact of the M184V mutation in human 
immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother, 2003. 47(11): p. 
3377-83. 
265. Johnson, J.A., et al., Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing 
and allow linking of resistance mutations. PLoS One, 2007. 2(7): p. e638. 
266. Brennan, T.P., et al., Analysis of human immunodeficiency virus type 1 viremia and provirus in resting 
CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol, 
2009. 83(17): p. 8470-81. 
267. Dinoso, J.B., et al., Treatment intensification does not reduce residual HIV-1 viremia in patients on 
highly active antiretroviral therapy. Proc Natl Acad Sci U S A, 2009. 106(23): p. 9403-8. 
268. Allers, K., et al., Persistence of lamivudine-sensitive HIV-1 quasispecies in the presence of lamivudine in 
vitro and in vivo. J Acquir Immune Defic Syndr, 2007. 44(4): p. 377-85. 
269. Barbour, J.D. and R.M. Grant, The Clinical Implications of Reduced Viral Fitness. Curr Infect Dis Rep, 
2004. 6(2): p. 151-158. 
270. Deeks, S.G., Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet, 2003. 362(9400): p. 
2002-11. 
271. Brenner, B.G., et al., Persistence and fitness of multidrug-resistant human immunodeficiency virus type 
1 acquired in primary infection. J Virol, 2002. 76(4): p. 1753-61. 
272. Cong, M.E., W. Heneine, and J.G. Garcia-Lerma, The fitness cost of mutations associated with human 
immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol, 2007. 
81(6): p. 3037-41. 
273. Martinez-Picado, J., et al., Antiretroviral resistance during successful therapy of HIV type 1 infection. 
Proc Natl Acad Sci U S A, 2000. 97(20): p. 10948-53. 
274. Bunnik, E.M., et al., Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary 
intermediates using ultra-deep pyrosequencing. PLoS Pathog, 2011. 7(6): p. e1002106. 
275. Salemi, M., et al., Phylodynamics of HIV-1 in lymphoid and non-lymphoid tissues reveals a central role 
for the thymus in emergence of CXCR4-using quasispecies. PLoS One, 2007. 2(9): p. e950. 
276. Rieder, P., et al., Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and 
tropism in 145 patients with primary HIV-1 infection. Clin Infect Dis, 2011. 53(12): p. 1271-9. 
277. Troyer, R.M., et al., Changes in human immunodeficiency virus type 1 fitness and genetic diversity 
during disease progression. J Virol, 2005. 79(14): p. 9006-18. 
278. Huse, S.M., et al., Accuracy and quality of massively parallel DNA pyrosequencing. Genome Biol, 2007. 
8(7): p. R143. 
279. Loman, N.J., et al., Performance comparison of benchtop high-throughput sequencing platforms. Nat 
Biotechnol, 2012. 
280. Margulies, M., et al., Genome sequencing in microfabricated high-density picolitre reactors. Nature, 
2005. 437(7057): p. 376-80. 
 
 
